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Abstract 
 
Over the past 8 years, the discovery of 11 new human polyomaviruses (HPyVs) has 
revived interest in this DNA tumor virus family. Although HPyV infection is widespread 
and largely asymptomatic, one of these HPyVs, Merkel cell polyomavirus (MCPyV), is a 
human tumor virus. JC virus (JCPyV), BK virus (BKPyV), HPyV7, and trichodysplasia-
spinulosa virus (TSPyV) can cause non-neoplastic diseases in the setting of 
immunosuppression.  Probably, one of the most common themes among the oncogenic 
viruses rests in the ability of one or more of the viral proteins to deregulate pathways 
involved in the control of cell proliferation. 
The focus of this work is on MCPyV, which is a human pathogen. In addition to its 
importance in human health, there is growing interest in adapting MCPyV for drug 
delivery and other biotechnology applications, several viral coat proteins can 
spontaneously assemble into capsids in vitro with morphologies identical to the native 
virions and virion assembly is a powerful model system for studying protein complex 
formation.  The protein capsid of the virion is a non-covalent association of protein 
subunits that is responsible for an array of functions, including cell attachment, cell entry, 
and DNA release. Even for the best studied family members, the mechanism of assembly 
is still poorly understood. 
Studies on the proteins of MCPyV provide information about the composition of the 
virus, as well as individual virus-virus protein and virus-host protein interactions. Mass 
spectrometry offers a unique perspective on the properties of viruses. Its broad 
application to viral structure provides unique insights into many biological processes, 
including viral–antibody binding, protein–protein interactions and protein dynamics. 
Electrospray ionization (ESI) mass spectrometry is a powerful approach for analyzing 
biomolecules and biomolecular complexes. Previous studies have provided evidence that 
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non-covalent biomolecular complexes can be observed by ESI mass spectrometry.  Mass 
spectrometry of viral proteins is now routine and since viruses are typically well 
characterized, in that the capsid protein and genome sequences are known, identifying a 
virus based on the mass of the protein or based on enzymatic digestion is relatively 
straightforward. 
This thesis describes the use of mass spectrometry for the identification of proteins 
associated with the MCPy virion and for the analysis of the post-translational 
modifications of the capsid proteins, such as ubiquitinylation, phosphorylation and 
acetylation.  
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1. INTRODUCTION 
 
1.1 Viruses 
 
The first viruses were discovered at the end of the nineteenth century by the Russian 
botanist Iwanowski who demonstrated that the extracts of a diseased plant could 
transmit the disease to healthy plants, even after passing through fine filters. At that point 
a virus (from the Latin for poison) was called “soluble living germ” (Cann 2001). 
Viruses are organisms that cause diseases that depend largely on their host for survival 
and reproduction because they can only multiply within cells. Viruses are the smallest 
known organisms and it was not until the 1930s that it was possible to separate viruses 
from their host cell material. Studies of bacterial viruses, e.g. bacteriophages, in the 1940s, 
confirmed that viruses consist of genetic material (RNA or DNA) and a protein shell, the 
capsid, which surrounds it (Hershey, Chase 1952). The capsid helps to transport the virus 
and it also protects the virus from degradation when it is outside of cells. Many viruses 
also have a lipid envelope surrounding the capsid. Each virus type can only infect a limited 
range of hosts and some viruses can only infect one species. Viruses are also normally 
tissue specific, for example some common cold viruses only infect cells of the upper 
respiratory tract. 
The isolated viral particles are incapable of reproducing without assistance, because they 
lack enzymes and all the other equipment necessary to produce their own proteins. 
However, when they enter a host cell, they take control of the cellular machinery to 
promote their reproduction. This multiplication of the virus is often lethal to the infected 
cell, which in turn lyses, and releases numerous new viral particles that infect new cells. 
Many of the symptoms of a viral infection are due to this tissue damage, but also due to 
17 
 
the activation of the immune system, e.g. the inflammatory responses (Rous, Landmark 
1983). 
The immune system typically manages to control the virus within a few weeks. However, 
some viruses do not kill the cell; and are able to integrate their genes into the host 
genome and can remain more or less dormant in the host inducing a persistent, latent, or 
recurrent viral infection. Some of these viruses may contain genes that regulate cell 
growth and can transform normal cells into cancer cells and these are the tumor viruses 
(Gross 1953). 
 
1.2 Viruses and Cancer 
 
About 20 % of all cancer cases worldwide are believed to be caused by viruses (Parkin 
2001; Parkin 2006). The strongest link is between Human Papilloma Virus (HPV) and 
cervical cancer, where the virus has been estimated to be responsible for 93% of the 
cervical cancers (Bosch et al. 1995). Moreover, liver cancer is linked to Hepatitis B and C 
viral infection (Bradley 1999). Epstein-Barr virus (Burkitt's lymphoma), human herpes virus 
(Kaposi’s sarcoma) and human T-lymphotropic retrovirus (leukemia) also represent 
identified human tumor viruses (Zur Hausen 1999). The first tumor virus was discovered 
by Francis Peyton Rous more than 100 years ago and considerable research has been 
devoted to understanding this group of viruses (Rous 1910). Vaccination programs for the 
prevention of two common tumor virus infections, hepatitis B virus (HBV) and HPV have 
begun to make a difference in the burden of cancer and the general health of the world 
population (Goldie et al. 2004; Lavanchy 2004). 
Francis Peyton Rous showed that viruses could induce cancer. He transplanted sarcoma 
from a 15-month old hen into other chickens using cell-free tumor extracts (Rous 1910; 
Rous 1983). The isolated etiologic agent, Rous sarcoma virus (RSV), was the first tumor 
virus identified. It took 50 years, with Ludwik Gross’s discovery of an acute transforming 
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murine retrovirus and a polyomavirus that caused murine tumors (Gross 1953), for the 
interest in tumor viruses to re-emerge. The impact of these achievements was enormous. 
Just after Rous received the Nobel Prize for his discoveries other studies of the Rous 
Sarcoma Virus resulted in the discoveries of reverse transcription and the cellular origin 
of viral oncogenes (Stehelin 1976; Baltimore 1970). 
The first tumor viruses were discovered in fowls by Rous in 1911 (Rous 1910 and Rous 
1911). In the 1930s, Rous et al., infected rabbits with cottontail rabbit papillomavirus and 
found that the rabbits developed tumors (Rous 1936). In 1951 Gross found the first 
murine tumor virus, the murine leukemia virus (MLV) (Gross 1951). Regarding human 
tumor viruses, it was not until 1976, that Zur Hausen could demonstrate that human 
papillomavirus (HPV) causes cervical cancer (Zur Hausen 1976). Numerous tumor viruses 
have been identified that include members of the retrovirus, polyomavirus, adenovirus 
and herpesvirus groups (McLaughlin-Drubin and Munger 2008). 
 
1.3 Human tumor viruses  
 
The first human tumor virus was discovered in 1964 by Anthony Epstein, Bert Achong 
and Yvonne Barr. They identified herpesvirus-like particles in cell lines from African 
patients with an unusual, geographically confined childhood cancer called Burkitt’s 
lymphoma (Epstein, Barr 1964). The virus was subsequently named the Epstein-Barr virus 
(Golden 1968). Although studies that showed EBV infection is ubiquitous in adults 
worldwide, EBV-associated tumors were rare. The dissociation between infection and the 
onset of cancer confounded scientists on how viruses cause tumors (Proceedings of the 
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 1997; Griffin 2000). In 
addition, sporadic Burkitt lymphomas, often lacking EBV, have been observed in 
developed countries, but these cases often maintain a characteristic mutation of Burkitt's 
lymphoma (Kelly and Rickinson 2007). Understanding how cancer developes and the 
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recognition that chronic viral infections work together with various non-viral host factors 
to contribute to cancer, ultimately led to the acceptance of EBV as a human cancer virus. 
The International Agency for Research on Cancer (IARC) declared EBV as a Group I 
human carcinogen in 1997 (No. 70 IARC Working Group on the Evaluation of Carcinogenic 
Risk to Humans. Lyon (FR): International Agency for Research on Cancer; 1997). Scientists have 
made numerous attempts to search for human tumor viruses using a similar electron 
microscopy approach, however these were mostly negative. It was later understood that 
oncogenic viruses generally do not replicate as virions in tumors, but exist as latent 
episomes or physically integrated into the host genome (Berger, Concha 1995; Imperiale 
2000). Many other classes of human tumor viruses have been identified since EBV (Table 
1.1). Interestingly, almost all of these human tumor viruses have closely related family 
members that do not cause human cancer. 
  
20 
 
 
Table 1.1 Human tumor viruses (from Moore, Chang, 2010) 
Virus Year 
identified 
Method of 
identification 
Genome Cancer associations Reference 
 
 
 
Epstein–Barr virus (EBV) 
 
 
 
1964 
 
 
 
Electron microscopy 
 
 
Double-
stranded DNA 
herpesvirus 
Most Burkitt's lymphoma 
and nasopharyngeal 
carcinoma, most 
lymphoproliferative 
disorders, some Hodgkin's 
disease, some non-
Hodgkin's lymphoma and 
some gastrointestinal 
lymphoma 
 
 
Epstein et al., Lancet, 
1964 
 
 
Hepatitis B virus (HBV) 
 
 
1965 
 
 
Serologic screening 
Single-stranded 
and double-
stranded DNA 
hepadenovirus 
 
Some hepatocellular 
carcinoma 
 
Blumberg et al., 
JAMA, 1965 
Human T-
lymphotropic virus-I 
(HTLV-I) 
 
1980 
 
Tissue culture 
Positive-strand, 
single- stranded 
RNA retrovirus 
 
Adult T cell leukaemia 
Poiesz et al., PNAS, 
1980 
 
High-risk human 
papillomaviruses 
(HPV)  
 
 
1983–1984 
 
 
DNA cloning 
 
Double-
stranded DNA 
papillomavirus 
Most cervical cancer and 
penile cancers and some 
other anogenital and 
head and neck cancers 
Durst et al., PNAS, 
1983 Boshart et al., 
EMBO J, 1983 
Hepatitis C virus (HCV) 1989 cDNA cloning 
Positive-strand, 
single- stranded 
RNA flavivirus 
Some hepatocellular 
carcinoma and some 
lymphomas 
Choo et al., Science, 
1989 
Kaposi's sarcoma 
herpesvirus (KSHV) 
 
1994 Representational 
difference analysis 
Double-
stranded DNA 
herpesvirus 
Kaposi's sarcoma, primary 
effusion lymphoma and 
some multicentric 
Castleman's disease 
Chang et al., Science, 
1994 
Merkel cell polyomavirus 
(MCV) 
2008 
Digital transcriptome 
subtraction 
Double-
stranded DNA 
polyomavirus 
Most Merkel cell carcinoma 
Feng et al., Science, 
2008 
 
 
In adults, primary HBV infection causes either acute hepatitis or may be asymptomatic. 
However, in about 5% of infected infants and adults where the primary infection fails to 
resolve, a chronic infection is observed. Persistent chronic infection, along with other risk 
factors, increases the risk of developing hepatocellular carcinoma (Shah 2004; Carbone et 
al. 1997). 
HBV-induced liver cancer is responsible for more than 300,000 deaths a year worldwide. 
An important milestone in the prevention of these tumors was provided by Merck's HBV 
vaccine. It is a recombinant vaccine produced in yeast cells and protects against not only 
acute and chronic hepatitis, but also the development of HCC (Javier, Butel 2008). 
HTLV-1, the first retrovirus that causes human cancer was discovered in the 1980’s 
(Poiesz et al. 1980). HTLV-1 infects healthy individuals, but is kept in check by the immune 
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system and remains latent/dormant for long periods. HTLV-1 infection causes a life-long 
infection for infected subjects. HTLV-1 is endemic in various parts of the world and it has 
been estimated that over 10 million individuals are infected with HTLV-1 (Edlich et al. 
2003), but most infected persons are asymptomatic. 
Cervical cancer is the third most common cancer in women worldwide (Smith et al. 
2004). Based on the emerging evidence at the time, linking human papillomaviruses (HPV) 
to gential warts, Harald zur Hausen reasoned that HPV was the etiologic agent for 
cervical cancer, despite the general belief that herpes simplex virus 2 (a sexually 
transmitted virus) was the likely cause. In his landmark studies in 1983 and 1984, his 
group discovered two novel HPV genotypes (HPV16 and HPV18) (Tsai et al. 2003; Gilbert 
et al. 2004). These genotypes are now confirmed as the causative agents for 70% of 
cervical cancers worldwide. HPVs are associated with more human cancers than any 
other virus (Mannova et al. 2003; Friedet al. 1981; Sinibaldi et al. 1990; Liu et al. 1998). The 
success of the HBV vaccine prompted HPV biologists to develop a safe HPV vaccine. This 
was achieved by using quadrivalent virus like particles (VLP)-based on recombinant capsid 
protein L1 from HPV types 6, 11, 16 and 18) and clinical trials in 2006 demonstrated that 
immunized women had type-specific protection against HPV infection, as well as 
protection against associated cervical, vulvar and vaginal disease (Block et al. 2006). VLPs 
are non-infectious virions resulting from the self-assembly of viral capsid proteins, and are 
used in making conformational viral epitope-based vaccines (Michel et al. 1967). The 
vaccines, marketed as the quadrivalent Gardisil®9 and the bivalent CervarixTM, are 
widely used and recommended for young individuals (both girls and boys, ages 9 through 
26). Based on current estimates, these vaccines can lead to the prevention of greater than 
400,000 cervical cancer cases per year. 
Investigations of viruses as agents of human neoplasms led to the discovery of two new 
human tumor viruses, KSHV and MCPyV. Kaposi's sarcoma-associated herpesvirus 
(KSHV) is the virus that causes Kaposi's sarcoma (KS), the most common neoplasm that 
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occurs in individuals with untreated HIV / AIDS. Kaposi sarcoma oncogenesis has been 
shown to be associated with loss of T-cell-mediated control of KSHV-infected cells. 
KSHV can establish an asymptomatic infection for life in immunocompetent subjects and 
when the number of T cells decreases (AIDS or treatment with immunosuppressive 
drugs) both the prevalence of KSHV infection and the incidence of KS in KSHV carriers 
increases significantly (Chang et al. 1994; Robey et al. 2010). 
Merkel cell carcinoma is a rare and aggressive primary skin tumor that often has a poor 
prognosis (Gheysen et al. 1989; Delchambre et al. 1989). The risk of developing MCC is 13 
times higher in patients with AIDS and 10 times higher after solid organ transplantation 
(French et al. 1990). MCC is also more common in patients undergoing 
immunosuppressive therapy, in elderly subjects and in patients with other tumors such as 
chronic lymphatic leukemia, basal cell carcinoma and squamous cell carcinoma. 
Importantly, none of these tumors has being casually associated with MCPyV infection 
(Reety et al. 2012). Based on the strong association between immunosuppression and its 
epidemiology, Merkel Cell Carcinoma (MCC) was subjected to a direct sequencing 
method called Digital Transcriptome Subtraction (DTS) designed to discover viral 
sequences (Murata et al. 2003; Paliard et al. 2000). cDNA libraries were created from the 
mRNA of four MCC tumor tissues and sequenced to generate a transcriptome database 
of MCC tumors. An in silico subtraction of known human sequences using databases of 
human genomic sequences (made available through the Human Genome Project) 
identified non-human sequence candidates for further testing.  From these candidate 
sequences, a transcript with homology to other poliomaviruses was identified, which 
paved the way for the discovery of a new polyoma virus associated with MCC (GenBank 
access numbers EU375803 and EU375804) (Murata et al. 2003). 
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1.4 Polyomaviruses  
 
1.4.1 Classification  
 
The name Polyomaviridae derives from the study of the first discovered member of this 
family, the murine polyomavirus (MPyV) that was discovered by Gross in 1953.  He noted 
that MPyV induced multiple (poly: Greek meaning many) tumors (oma: Greek meaning 
tumors) when injected into mice. Polyomaviruses have been found in mammals and birds. 
The genome sequences of 30 polyomaviruses have been deposited in GenBank, including 
more than 10 disinct viruses infecting humans (Figure 1.1) (Van Ghelue et al. 2012). 
The first Human polyomaviruses, BK and JC, named using the affected patients’ initials, 
were isolated in 1971 from the urine of a kidney transplant recipient and from the brain 
of a Hodgkin lymphoma patient, respectively (Gardner et al. 1971; Padgett et al. 1971). 
Others new viruses were found using DNA sequencing techniques. In 2007, the 
Karolinska Institute (KI) and Washington University (WU) polyomaviruses (KIPyV and 
WUPyV) were found in nasopharyngeal aspirates. In 2008, the Merkel cell polyomavirus 
(MCPyV) was discovered in Merkel cell carcinoma transcriptomes (Feng et al. 2008). 
HPyV-6 and HPyV-7 were found in skin swabs of healthy individuals in 2010 (Schowalter et 
al. 2010). In the same year, Trichodysplasia spinulosa (TS) associated polyomavirus 
(TSPyV) was found in a patient with the rare skin disease TS (Van der Meijden et al. 2010). 
To date, the latest HPyVs described are HPyV-9, and HPyV-10 which were found in the 
serum of a kidney transplant patient (Scuda et al. 2011) and in skin specimens of a patient 
with a rare genetic disorder known as myelokathexis syndrome (Buck et al. 2012). One 
more possible Human polyomavirus was identified in a child from Malawi and named 
Malawi polyomavirus (MWPyV) (Siebrasse et al. 2012). HpyV-10 and MWPyV are likely to 
be the same virus as sequence similarity of these is greater than 95% (Buck et al. 2012). 
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This close relationship is also seen in a phylogenetic tree of the polyomaviruses and is 
also indicates that MCPyV is the most distant family member (Figure 1.1). 
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1.4.2 Morphology, genomic arrangement and viral proteins  
The polyomaviruses are non-enveloped small viruses with a circular double-stranded 
DNA (dsDNA) genome of ~5000 base pairs. The genome is packaged in an icosahedral 
(T=7 symmetry) capsid of approximately 40-45 nanometers in diameter (Figure 1.2). 
Capsids are composed of 72 pentameric capsomeres of the VP1 protein, which is capable 
of self-assembly into a closed icosahedron; (Salunke et al. 1986) with each VP1 pentamer 
associated with one of the other two capsid proteins, VP2 or VP3 (DeCaprio et al. 2013).  
The MCPyV capsid consists of the structural proteins VP1 and VP2 in a ratio of 5:2, the 
VP3 protein, is not incorporated into MCPyV capsids but it is found in other 
polyomaviruses. Polyomavirus genomes are divided into two transcriptional regions called 
the early (ER) and the late region (LR) encoded on opposite strands (Figure 1.3). The 
early region usually codes for two proteins, the Large T antigen (LTAg) and the Small T 
antigen (sTAg). LTAg is a multifunctional nuclear phospho-protein with distinct roles in 
promoting viral DNA replication by forming a complex with cellular replication proteins, 
unwinding the viral genome and stimulating cell-cycle advancement into S- phase. In order 
to stimulate S-phase entry, LTAg inactivates both the p53 and the retinoblastoma (pRB) 
tumor suppressor pathways (Hermannstadter et al. 2009; Kazem et al. 2014). LTAg-
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induced cell-cycle progression is the principal contributor to oncogenic transformation, 
because the expression of LTAg alone is sufficient to cause tumor formation in many 
systems (Cheng et al. 2009). The sTAg stimulates viral DNA replication and the sTAg C-
terminus binds to and deregulates the PP2A phosphatase (Sullivan et al. 2005). Without 
sTAg, polyomaviruses are viable, but grow more slowly and less productively. 
The late region (LR) contains the three capsid proteins VP1, VP2, and VP3 (Decaprio et al. 
2013). Avian polyomaviruses contain a VP4 capsid protein (Johne et al. 2007), and some 
mammalian polyomaviruses produce an agnoprotein that is involved in transcription, virus 
maturation and release. SV40 encodes a 17 kT protein that is produced by alternative 
splicing of the LTAg transcript (Zerrahn et al. 1993) (Figure 1.4).  Each region is 
transcribed by the host cell’s RNA polymerase II, as a single pre-messenger RNA 
containing multiple genes. These two regions are separated by a non-coding regulatory 
region (NCCR) containing the origin of replication (ori) and binding sites for transcription 
factors (Figure 1.3). 
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1.4.3 Simian Virus 40 
The Simian 40 virus (SV40), also called the vacuolating virus of the monkey, is a 
polyomavirus found in monkeys (Macaques Rhesus), and as a zoonotic infection in humans 
(Shah 2004). SV40 infection has been shown to transform tissue culture cells and cause 
tumors in laboratory animals. The virus was first described in 1960, in a culture of 
monkey kidney cells used to produce the polio vaccine (Sweet et al. 1960). This vaccine 
was administered to over 100 million people from 1955 to 1963 and the possibility that 
SV40 causes human diseases, especially cancer, has been the subject of debate ever since. 
For example, it has been described that SV40 is present in mesotheliomas in humans 
(Carbone et al. 1997), but fortunately, an important role of this virus in human tumors has 
not been established. 
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1.4.4 Viral life cycle  
 
The polyomavirus life cycle begins with the interaction of the VP1 capsid proteins with 
sialic acid or other ganglioside receptors. Ganglioside GM1 is the best characterized 
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receptor for SV40, GD1a and GT1b for MPyV, GD1b and GT1b for BKV, GT1b and the 
serotonin receptor 5HT2AR for JCV and GT1b and heparin sulphate, a 
glycosaminoglycan, for MCPyV (Tsai et al. 2003; Low et al. 2006; Elphick et al. 2004; 
Erickson et al. 2009). Gangliosides are components of the plasma membrane that comprise 
glycosphingolipids with one or more sialic acids. Whenever the virus binds to the 
receptor, the initial phase of the life cycle proceeds with internalization of the virus 
through caveole, or clathrin-dependent endocytosis (Eash et al. 2006). Cellular factors in 
the lipid bilayer of the internalized vessicle allow for the release of the viral genome into 
the cytoplasm. Viral DNA passes into the nucleus where transcription factors are 
recruited to induce transcription of the early region. This results in the expression of 
LTAg and sTAg which promotes entry of the infected cells into S phase, where LTAg 
recruits cellular DNA replication factors and initiates DNA replication of the viral 
genome from the origin in the NCRR (Simmons, 2000). The start of viral replication leads 
to transition into the late phase of the viral life cycle. Viral DNA replication progresses 
bidirectionally on the circular genome, involving leading and lagging strands. When the 
two-replication forks meet, replication terminates (Fanning et al. 2009). LTAg activates 
transcription from the late gene promoter and represses the early promoter. This results 
in the expression of the capsid proteins, which then assemble into capsids and 
encapsulate the viral genome. Virus is released by cell lysis and the process can begin 
again. An SV40 infection cycle takes 3-4 days in permissive cells (such as African green 
monkey cells) in vitro, eventually resulting in cell death and the production of ~300 
infectious progeny virions per infected cell (Pipas 2009) (Figure 1.5). 
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In human systems, only the life cycles of JCPyV and BKPyV have been well studied.  
During the lytic phase, the virus attaches onto the cell surface via receptors such as 
gangliosids and the serotonin receptor (Elphick et al. 2004; Erickson et al. 2009; Low et al. 
2006). The virus is trafficked through the caveolae and the endoplasmatic reticulum (RE) 
to the nucleus, where it is uncoated and the early region is transcribed. Caveolae are 
dedicated lipid rafts that form 50-70 nm flask-shaped invaginations of the plasma 
membrane. The virion is presumably internalized in the caveolae on binding to host 
receptors.  In the case of JCPyV this process is clathrin-dependent and the clathrin coated 
vesicles mature into late endosomes. The maturation is accompanied by a pH acidification 
down to pH 6.0, which promotes uncoating of the viral genome (Eash et al. 2006).  
After transcription and translation, LTAg begins to promote DNA replication of the viral 
genome. The shift to late viral protein expression is not fully clear, but likely involves 
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transcriptional activation of the late promoter and repression of the early promoter by 
LTAg (Gjoerup et al. 2010). Capsid proteins assemble around the replicated genomes to 
form new mature virions, which are released by mechanisms that include cell lysis (Atkin 
et al. 2009).  
The cell-transforming properties have been studied using the model polyomaviruses SV40 
and the murine polyomavirus (MPyV), both of which induce tumours in mice. 
Transformation is largely the result of a failed lytic infection, either because the host cell 
is not permissive for replication or because the virus is defective in replicative functions. 
This non-replicative viral DNA can integrate into the host genome randomly and typically 
infective virus cannot be isolated from tumour material (Atkin et al. 2009).   
 
1.4.5 Human polyomaviruses. 
 
So far nine human polyomaviruses have been identified (Table 2). The JC virus (JCPyV) 
and the BK virus (BKPyV), which take their names from the initials of their respective 
patients, were the first human polymaviruses to be discovered. They were isolated from 
cultures of diseased tissues of immunosupressed patients, JCPyV from brain tissue of a 
progressive multifocal leukoencephalopathy pateint and BKPyV from the urine of a patient 
with nephropathy and poor renal function (Gardner et al. 1971; Padgett et al. 1971). JCPyV 
has a limited tissue tropism and infects only kidney, bone marrow, oligodendrocytes and 
astrocytes (Maginnis et al. 2009). The researchers found that in animal models, JCPyV 
causes tumors in rodents and primates (Houff et al. 1983; WT et al. 1978; Ohsumi et al. 
1986; Ohsumi et al. 1985; Walker et al. 1973; Horie et al. 1989). As with JCPyV, the 
expression of BKPyV early region (ER) also transforms mouse and hamster cells and 
immortalizes human cells (Grossi et al. 1982; Portolani et al.  1978). BKPyV inoculation of 
newborn mice, rats and hamsters causes various tumors including ependymoma, 
neuroblastoma, fibrosarcoma and osteosarcoma (Tognon et al. 2003; Corallini et al. 1982). 
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Based on these results, many studies investigated the link between JCPyV and BKPyV and 
various cancers (brain, colorectal and gastric), but an association between these viruses 
and any type of human cancer has not been made (Maginnis et al. 2009; Tognon et al. 2003; 
Imperiale 2000; Jiang et al. 2009; Caldarelli-Stefano et al. 2000; Jung et al. 2008; Ricciardiello et 
al. 2000; Laghi et al. 1999; Ricciardiello et al. 2001; Murai et al. 2007; Rencic et al., 1996; Shin 
et al. 2006). Both viruses are still common in the general population and maintain lifelong 
disease-free infection in immunocompetent individuals (Kean et al. 2009). Seroprevalence 
studies show an overall seroprevalence rate of 81-82% for BKPyV and 35-58% for JCPyV 
among healthy blood donors from the UK, Switzerland and the United States (Kean et al. 
2009; Knowles et al. 2003; Egli et al. 2009). Seroconversion occurs early in childhood and 
dampens in elderly individuals for BKPyV but increases steadily up to ~50% in 60-69 aged 
individuals for JCPyV (Knowles et al. 2003).  
In 2007 two more closely related human polyomaviruses were found by the Karolinska 
Institute (KIPyV) and the Washington University (WIPyV) polyomavirus. Both were 
isolated from children with acute respiratory tract infections by constructing cDNA 
libraries, deep sequencing, and BLASTing against NCBI databases for non-human 
sequences (Allander et al. 2007; Gaynor et al. 2007). Present experimental proof does not 
support causation of any respiratory disease and no other link between illnes and 
symptomatic infection has been found (Wattier et al. 2008; Zhuang et al. 2010; Ren et al. 
2008; Jartti et al. 2012). Both viruses show a wide geographic distribution and estimates of 
seroprevalence range widely from 1-65% among the general healthy population (Kean et 
al. 2009; Venter et al. 2009; Bialasiewicz et al. 2010; Bialasiewicz et al. 2007; Dang et al. 
2011; Furuse et al. 2010; Zhao et al. 2010). Three more polyomaviruses were discovered 
recently by using a method called rolling circle amplification (RCA). RCA is a random 
primer extension technique that uses a DNA-dependent polymerase that preferentially 
amplifies circular DNA and can displace an annealed DNA strand (Johne et al. 2009). 
During a search for MCPyV on skin surfaces using RCA, Schowalter et al. serendepitiously 
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discovered Human polyomavirus 6 and 7 (HPyV6 and HPyV7) from the skin of healthy 
humans (Schowalter et al. 2010). Subsequent studies failed to reveal any link between 
HPyV6 or HPyV7 and basal cell carcinomas, melanomas, and cutaneous B and T cell 
lymphomas (Schrama et al. 2012). The HPyV6 and HPyV7 are most similar to WUPyV and 
KIPyV and are classified into the WuKipolyomaviruses group in the new ICTV 
taxonomical classification (Johne et al. 2011). 
 
Table 1.2: Human Polyomaviruses (From Chang & Moore, Annual Reviews Pathology 2011) 
 
  
 
Virus 
Year 
identified 
 
Method of 
identification 
Prevalence 
in human 
population 
 
Disease 
associations 
 
Geno
me 
size 
 
GenBank 
 
Reference 
 
BK virus 
(BKV) 
 
1971 
 
Culture isolation 
from urine of 
renal transplant 
recipient 
 
>90% of adults 
 
Cystitis, 
polyomavirus- 
associated 
nephropathies, 
ureteral stenosis 
 
5153bp 
 
NC_001538 
 
Gardner et 
al., Lancet, 
1971 
 
JC virus 
(JCV) 
 
1971 
Culture isolation from 
brain tissue with 
progressive multifocal 
leukoencephalopathy 
 
>70% of adults 
Progressive 
multifocal 
leukoencephalopa
thy 
 
5130bp 
 
NC_001699 
Padgett et 
al., Lancet, 
1971 
Karolinska 
Institute 
polyomaviurs 
(KIV) 
2007 
Deep sequencing of 
DNAase-treated 
respiratory fluids 
55–70% of 
adults 
Not defined 5040bp NC_009238 
Allander et 
al., JVI, 2007 
Washingt
on 
University 
polyomavi
rus 
(WUV) 
 
2007 
Deep sequencing of 
DNAase- treated 
respiratory fluids 
from children with 
upper respiratory 
infections 
 
69–80% of 
adults 
 
Not defined 
 
5229bp 
 
NC_009539 
 
Gaynor et 
al., PLoS 
Pathogens, 
2007 
Merkel cell 
polyomaviru
s (MCV) 
 
2008 
Digital 
transcriptome 
subtraction of 
Merkel cell 
carcinoma tissue 
42–70% of 
adults 
 
Merkel cell 
carcinoma 
 
5387bp 
 
NC_010277 
Feng et al., 
Science, 
2008 
Human 
Polyomavirus 
6 (HPyV6) 
 
2010 
Rolling-circle 
amplification of skin 
and hair samples 
 
Not defined 
 
Not defined 
 
4926bp 
 
NC_014406 
Schowalter 
et al., Cell 
host&micro
be, 2010 
Human 
Polyomavirus 
7 (HPyV7) 
 
2010 
Rolling-circle 
amplification of skin 
and hair samples 
 
Not defined 
 
Not defined 
 
4952bp 
 
NC_014407 
Schowalter 
et al., Cell 
host&micro
be, 2010 
Trichodyspl
asia 
spinulosum 
polyomavir
us (TSV) 
2010 
Rolling-circle 
amplification of 
trichodysplasia 
spinulosum lesion in 
transplant recipient 
Not defined 
Transplant-
associated 
trichodysplasia 
spinulosum 
5232bp NC_014361 
Van der 
Meijden 
et al., 
PLoS 
Pathogen
s, 2010 
Human 
Polyomavirus 
9 (HPyV9) 
2011 
Consensus PCR 
and deep 
sequencing 
Not defined Not defined 5026bp NC_015150 
Scuda et al., 
JVI, 2011 
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An eighth human polyomavirus was isolated in 2010 from virus-associated trichodysplasia 
spinulosum (VATS), a rare type of dysplasia seen only in transplant and 
immunosuppressed patients. Based on previous ultrastructural detection of polyomavirus 
like particles in VATS (Wyatt et al. 2005) and its close association with 
immunosuppression, van der Meijden and collaborators applied RCA to VATS tissue and 
found trichodysplasia spinulosum polyomavirus (TSaPyV) (Van der Meijden et al. 2010). 
TSaPyV exhibits abundant expression of viral proteins only in the affected hair follicles, 
suggesting a causative role in trichodysplasia spinulosa disease (Tan et al. 2011; Kazem, et 
al. 2012). In 2011, HPyV9 was identified from the serum of an immunosuppressed kidney 
transplant patient by using consensus PCR (Scuda et al. 2011). Most of these recently 
discovered human polyomaviruses appear to be previously unrecognized infections with a 
high seroprevalence in the general population. With improvement of detection techniques 
and assays the subfamily of human polyomaviruses is likely to expand with new 
polyomaviruses being linked to disease as well as being part of the normal human 
microbial flora. 
 
1.4.6 SV40 Tag - classic models for studying cancer 
 
The Polyomaviruses, and in particularly SV40, have been used as model systems for 
understanding the basic cellular biology relating to cellular immortalization and oncogenic 
transformation. Since they were discovered, studies on Polyomaviruses and their target 
pathways have lead to critical insights into key biological processes. These viruses rely on 
the multifunctional T antigen proteins and the cellular machinery to carry out various 
functions in their life cycle (Pipas 2009; Pipas 1992).The TAgs start by reprogramming the 
host cell cycle to induce progression into the S-phase, creating an optimal environment 
for viral replication. This is especially important for SV40 infection in its natural host 
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rhesus macaque, because SV40 typically infects non-cycling, growth-arrested, epithelial 
cells of the kidney (Ahuja et al. 2005). 
Changes in cell morphology, anchorage independent growth, loss of density-dependent 
growth inhibition, a decrease in the dependence on serum growth factors, and the ability 
to form tumors in animal hosts are indicators that distinguish a tumor cell from a normal 
cell (Raptis et al. 2001; Hanahan et al. 2011). Multiple assays have been developed to study 
the transformation phenotype induced by SV40 and other polyomaviruses. In each of 
these assays, cells are cultured under conditions of selective growth pressure so that only 
the transformed cells are able to survive and proliferate, whereas the normal cells die or 
enter senescence. These form the basis by which SV40 and other polyomaviruses ability 
to transform cells have been assessed (Raptis et al. 2001). 
 
1.4.7 Large tumor antigen (LTAg) 
 
SV40 TAgs target and modify different cellular pathways that are important for preparing 
the cellular environment for DNA replication and these pathways have also proven to be 
important for the ability of TAgs to transform cells. 
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The nuclear phosphoprotein LTAg is multifunctional, which is seen in its modular 
structure. LTAg has discrete regions corresponding to the binding domains of various 
interaction partners. Some of these interaction partners include pRB, p53, p107, p130, 
Hsc70, Cul7, p300/CBP, and FBW7 (Figure 1.6) (Sullivan et al. 2002; Ahujaet al. 2004; Ali et 
al. 2004; Cotsiki et al. 2004; Fei et al. 1995; Srinivasan et al. 1997; Stubdal et al. 1997; Stubdal 
et al. 1996; Yaciuk et al. 1991; Lill et al. 1997; DeCaprio et al. 1988; Lane et al. 1979; Linzer 
et al. 1979). Two of the most important tumor suppressor genes, p53 and the 
Retinoblastoma protein (pRB), were either discovered or functionally dissected as a result 
of their interaction with SV40 LTAg (Dilworth 2002; Pipas 1992; Butel et al. 1999). 
 
1.4.8 Interaction with pRB family of proteins 
 
Today, we know that most tumor viruses target memberts of the pRB pathway for 
inactivation. Polyomavirus LTAgs share a highly conserved LXCXE motif, which binds to 
RB family proteins (DeCaprio et al. 1988; DeCaprio 2009; Chen et al. 1990; Dyson et al. 
1989; Munger et al. 1989; Whyte et al. 1988). The majority of cancers (viral and non-viral) 
contain alterations in the regulation of the pRB pathway (Burkhart, et al. 2008). This shows 
a common mechanism shared between viruses in targeting specific cellular proteins and 
proves the importance of this protein family in tumorigenesis. 
Knudson and collaborators first identified the pRb gene in 1971. They performed a 
genetic study demonstrating that childhood retinoblastoma had a hereditary element, and 
concluded that two separate mutation events were responsible for development of the 
disease. In hereditary retinoblastoma, the child inherited a mutated gene and obtained a 
second mutation in a somatic cell. In contrast, two independent mutations in the same 
somatic cell (later found to be two alleles of the same gene (Godbout et al. 1983; Comings 
1973) led to the development of sporadic retinoblastoma (Knudson Jr. 1971). The gene 
was then mapped to chromosome 13q14 and cloned.  The gene encodes for a nuclear 
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phosphoprotein of 110kDa (Lee et al. 1987). The fact that pRB undergoes 
phosphorylation in a cell cycle-dependent manner provided an important insight into its 
function. pRb protein is hypo-phosphorylated, in the G0 phase of quiescent or 
differentiated non-cycling cells and in the G1 phase of cycling cells. In this state, pRb binds 
to E2F transcription factors and inhibits the transcriptional activity of genes having E2F-
dependent regulatory elements. pRb is hyper- phosphorylated by cyclin dependent 
kinases, and phosphorylated pRb then releases the E2Fs, allowing them to stimulate the 
transcription of their target genes, which normally occurs as cells enter the S-phase of the 
cell cycle. The products of these genes then usher the cell from late G1-phase into S-
phase. Therefore, the hyposphosphorylated form of pRb functions as a tumor suppressor 
by preventing cells from entering S phase. 
pRb has been shown to mediate the transcriptional regulation of numerous target genes 
and has been reported to bind to over a hundred protein partners (Morris et al. 2001). 
The various cellular functions regulated by pRb include temporary and permanent cell 
cycle arrest, differentiation, genome stability and apoptosis.  
The first proof of a viral oncogene targeting a known tumor suppressor was the discovery 
that pRB is a target of the adenovirus E1A protein (Whyte et al. 1988). Subsequencet to 
this, Decaprio and collaborators showed that SV40 LTAg binds pRB and more intriguingly 
LXCXE mutants that are unable to bind pRB, failed to transform cells in a variety of cell 
types and assay systems (DeCaprio 2009; DeCaprio et al. 1988). To activate cell-cycle-
regulated genes, thus driving the cell into S-phase and increasing cell proliferation, DNA 
viruses must bind and sequester the hypophosphorylated form of pRb and free E2F 
transcription factors (Figure 1.7) (Reety Arora, Thesis Submitted for the PhD degree, University 
of Pittsburgh, USA 2012). The Retinoblastoma protein is composed of two domains, A and 
B, forming a pocket crucial for tumor suppression and is thus often referred to as a 
pocket protein (Burkhart et al. 2008). This region constitutes the binding site for the 
LXCXE motif and mutations in human malignancies usually map to this region. Despite, 
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the binding sites for both viral T antigens and E2F mapping to the pocket domain, they are 
distinct and pRB can bind both simultaneously. 
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Additional pocket proteins have been identified, such as p107 and p130 that also bind to 
the LXCXE domain of SV40 LTAg (Dyson et al. 1989; Ewen et al. 1989; Hannon et.al. 1993; 
Mayol et al. 1993). There are a number of properties that distinguish the three proteins 
and there is a central spacer domain in p107 and p130 that binds to CDK2: cyclin 
complexes and different Rb family members are responsible for binding to different E2F 
family members.  For example, pRB targets E2F1-3 (the “activating” E2Fs), in contrast 
p107/p130 targets E2F4/5 (the “repressing” E2Fs) (DeCaprio 2009). 
The importance of the LTAg HPDKGG/J domain in the inactivation of pRb was revealed 
by studies of SV40 LTAg. The model is that LTAg binds to the hypo-phosphorylated form 
of pRb and then recruits Hsc70 via this HPDKGG/J domain. The Rb-E2F complex first 
binds to LTAg and then it interacts with the substrate-binding domain of Hsc70.  ATP 
hydrolysis provides energy to Hsc70 that changes the conformation of the bound pRB, 
resulting in the release of E2F. (Kim et al. 2001; Zalvide et al. 1998).  
 
1.4.9 Interaction with p53 
 
The p53 tumor suppressor protein was discovered in 1979 as a cellular protein that binds 
to SV40 LTAg, both in SV40 transformed cells and infected cells (Lane et al. 1979; Linzer et 
al. 1979). It is now recognized that p53 is one of the most commonly mutated tumor 
suppressors and is found to be mutated in ~50% of human cancers (Hollstein et al. 1994).  
p53 is a DNA damage and cellular stress responsive transcription factor that regulates 
DNA synthesis and repair, induces cell cycle arrest, activates  apoptosis and cellular 
senescence and is also known as the “guardian of the genome” (Lane 1992). p53 is 
inactivated by most DNA viruses. Two well-known examples are adenovirus E1B 55k 
which binds and inactivates p53; together with E4orf6 that targets p53 for degradation, 
and human papillomavirus E6 protein, which also targets p53 for proteasomal degradation 
(Yew et al. 1992; Scheffner et al. 1990). 
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Within SV40 LTAg, the binding site of p53 is bipartite and is found at residues 351-450 
and 533-626 (Kierstead et al. 1993). The co-crystal structure of the LTAg ATPase domain 
bound to p53 revealed a region within the core DNA binding domain of p53 as 
interacting with LTAg (Lilyestrom et al. 2006). The interaction between T antigen and p53 
blocks p53- dependent gene expression by blocking p53 from binding to DNA (Lilyestrom 
et al. 2006; Bargonetti, et al. 1992). The ability of LTAg to bind p53 is not sufficient in many 
cases for transformation (Kierstead et al. 1993; Conzen et al. 1995). While one of the 
results of the interaction between LTAg and p53 is the prevention of a DNA damage 
response, the effects of this interaction are now known to be more complex. It is 
becoming clear that the effects of the LTAg and p53 interaction are not completely 
understood.  Some studies found that the interaction between LTAg and p53 also blocked 
LTAg replicative functions. Studies of growth phenotypes in the presence or absence of 
p53, or p53 mutants in assays of LTAg transformation led to the idea that LTAg stabilizes 
p53 and may induce it to acquire an unknown function (Hermannstadter et al. 2009; 
Tiemann et al. 1994; Deppert et al. 1989). The finding that wild-type p53 promotes tumor 
formation in LTAg transgenic mice is consistent with a gain of function phenotype (Herzig 
et al. 1999). One explanation may be that LTAg stabilizes p53 in order to gain access to 
p300/CBP, which then acts on promoters, or other LTAg bound proteins (Borger et al. 
2006). p53 mutants seen in cancers sometimes show a similar gain of function mutation 
(Brosh et al. 2009; Dittmer et al. 1993) and certain mutations in p53 may turn it into an 
oncogene. 
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1.4.10 Other interactions DnaJ Domain 
 
A common region shared in LTAg and sTAg, the HPDKGG motif, has been implicated in 
transformation (Campbell et al. 1997). This N terminal region of the two T antigens 
exhibits sequence and structural homology to DnaJ (Campbell et al. 1997). The chaperone 
DnaJ, also known as Hsp40, recruits other heat shock family proteins, the DnaK family 
members, for protein folding and protein transport. LTAg DnaJ domains bind to the 
constitutively expressed Hsc70 chaperone and stimulates its ATPase activity (Sullivan et al. 
2002; Srinivasan et al. 1997; Campbell et al. 1997). The D44N and H42Q mutants break up 
this interaction and have been used to show the importance of the T antigen DnaJ domain 
in viral replication and in oncogenic transformation (by functional inactivation of pRB 
family members) (Sullivan et al. 2002; Srinivasan et al. 1997; Campbell et al. 1997; Stubdal et 
al. 1997; Zalvide et al. 1998; Stubdal et al. 1996). The DnaJ domain’s contribution to LTAg 
mediated cellular transformation is limited to a subset of phenotypes. The D44N mutant 
affects the ability of LTAg to promote anchorage independent growth. (Stubdal et al. 
1997) and the DnaJ domain is required, along with the LXCXE motif, to disrupt the 
pRb/p107/p130 and E2F complexes and to promote growth in low serum, as well as 
allowing growth to a high saturation density (Stubdal et al. 1997; Sullivan et al. 2000; 
Zalvide et al. 1998). 
 
1.4.11 p300/CBP and p400 
 
Cyclic-AMP Response Element Binding (CREB)-protein and p300 are large scaffold 
proteins involved in transcriptional regulation. They act as co-activators, in part via their 
intrinsic histone acetylase (HAT) activity and mediate a number of biological processes, 
including cell growth and transformation and are thus considered tumor suppressors (Iyer 
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et al. 2004). Adenovirus E1A was first shown to bind p300/CBP and this binding was 
linked to adenovirus transformation and cellular DNA synthesis (Howe et al. 1990; Wang 
et al. 1993). Yaciuk and collaborators showed that pRB binding-deficient SV40 LTAg, but 
not DnaJ domain mutants, complemented p300/CBP binding- defective mutants of E1A to 
re-estabilish transformation in primary baby rat kidney cells (Yaciuk et al. 1991).  While 
early studies suggested LTAg’s CR1-like sequence as a binding site for p300/CBP, it was 
subsequently demonstrated that LTAg C terminal residues 251- 708 are responsible for 
the interaction (Lill et al. 1997; Eckner et al. 1996). Importantly, it was found that p53 
supported the binding of p300/CBP in a cooperative manner. The LTAg-CBP interaction 
results in the acetylation of LTAg on K697 and this acetylation also required p53 (Borger 
et al. 2006; Poulin et al. 2004). Work based on structure-guided mutational analysis of 
LTAg, indicated a direct binding of LTAg and p300/CBP proteins that is essential for 
oncogenic transformation (Ahuja et al. 2009). SV40 LTAg also binds to the p400 protein 
across its C terminal 251-708 segment, but the meaning of this interaction in LTAg-
mediated transformation is not clear (Lill 1997; Barbeau et al. 1994). p400 belongs to the 
SWI2/SNF2 family of chromatin remodeling proteins, it also interacts with a c-myc binding 
protein called TRRAP and is likely to be involved in the p53-p21 cellular senescence 
pathway and p53-dependent apoptosis (Fuchs et al. 2001; Samuelson et al. 2005; Chan et al. 
2005). 
 
1.4.12 Small tumor antigen (sTAg) 
 
The small tumor antigen (sTAg) is a protein expressed early in the infectious cycle and is 
usually not essential for viral proliferation. The sTAg protein is 174 amino acids long and 
its gene overlaps with the gene for LTAg. The two T antigens share the first 82 amino 
acids, which includes the DnaJ-like domain (Srinivasan et al. 1997). Although LTAg is a 
nuclear protein, sTAg is found both in the nucleus and cytoplasm. The C-terminus of 
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sTAg has two CXCXXC clusters that bind Zinc and confer conformational stability 
(figure 1.8) (Turk et al. 1993). sTAg is known to interact with host cell proteins, including 
phosphatase 2A (PP2A), and may activate the expression of cellular proteins associated 
with the cell cycle transition to S-phase. In SV40, sTAg is unable to induce neoplastic 
transformation in the host cell, but its presence may increase the transforming efficiency 
of LTAg. In Merkel cell polyomavirus, sTAg seem to be important for replication and 
appears to be the principle oncoprotein in MCPyV. 
 
 
 
 
 
 
 
 
 
 
1.4.13 PP2A 
 
The heterotrimeric protein phosphatase or Protein phosphatase 2 (PP2), known as PP2A, 
is a ubiquitously enzyme expressed in eukaryotic cells. It is a serine/threonine specific 
phosphatase and has a large substrate specificity and diverse cellular functions. PP2A is 
composed of an A scaffold subunit, a B regulatory subunit and a C catalytic subunit. There 
are two different A subunits, two different C subunits and 17 known B subunits that can 
assemble together, in various combinations, into more than 100 different holoenzyme 
complexes (Sablina et al. 2008; Sontag 2001). Several oncogenic signaling molecules, such 
as Raf, MEK, and AKT, are PP2A targets. Since the replication of the polyomavirus 
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genome is based on the DNA replication mechanism of the host cell, the host cell must 
be in S phase in order to provide the necessary molecular machinery for replication of 
viral DNA. The viral proteins promote entry into the S phase of the host cell cycle and 
this function is mainly provided by LTAg, through its interactions with pRb and the p53 
protein (Topalis et al. 2013; An Ping et al. 2012). The sTAg contributes to this process 
through its interaction with protein phosphatase 2A (PP2A). The functional role of sTAg 
changes among the polyomaviruses, for example in the SV40, sTAg has a small role in 
cellular transformation (Khalili et al. 2008). While in the Merkel cell poliomavirus, it 
appears to play a significant role in oncogenesis, a function performed primarily by LTAg 
in other polyomaviruses (Tsang et al. 2016). 
 
1.5 Merkel Cell Carcinoma 
 
1.5.1 Origin and pathology 
 
Merkel cell carcinoma (MCC) is a rare and highly aggressive skin cancer, which, in most 
cases, is caused by the Merkel cell polyomavirus (MCPyV) (Agelli et al. 2003; Hodgson 
2005). Initially named trabecular carcinoma of the skin, it was first described by Toker in 
1972 (Toker 1972). MCC was thought to derive from mechanoreceptor Merkel cells 
located at the basal layer of the epidermis (Figure 1.9). The Merkel cells play a role in the 
sensory system of the skin (Pearse 1980; Halata et al. 2003; Lucarz et al. 2007; Van 
Keymeulen et al. 2009; Haeberle et al. 2004; Maricich et al. 2009). Most common sites of 
MCC occur in sun-exposed areas such as the head and neck, followed by the lower and 
upper extremities and the trunk region. 
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1.5.2 Risk factors and clinical features 
 
The incidence of MCC, increases in elderly populations (median age = 65 years) (Heath et 
al. 2008) and in the immunosuppressed, for example following transplantation, immune-
related cancers, or AIDS, are other recognized risk factors (Agelli et al. 2010; Agelli et al. 
2003). MCC, like melanoma, shows a strong correlation to UV exposure (Miller et al. 
1999). The majority of the patients with MCC are fair skinned and MCC typically occurs 
in sun exposed areas of the skin (Agelli et al. 2003; Hodgson 2005; Allen et al. 2005). 
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1.5.3 Natural infection of HPyV and associated diseases  
 
All described HPyV, including MCPyV, are highly prevalent in the human population and 
infection starts during infancy. Seroprevalence is measured by IgG antibodies specific to 
the major capsid protein VP1. The seroprevalence peaks at 98% for WUPyV, 92% for 
BKPyV, 80% for JCPyV, 67% for KIPyV, 69% for HPyV-6, 35% for HPyV-7, more than 60% 
for MCPyV, about 70% for TSPyV and 47% for HPyV-9 (Chen et al. 2011; Faust et al. 2011; 
Kean et al. 2009; Knowles 2006; Neske et al. 2010; Van der Meijden et al. 2011; Viscidi et al. 
2011; Trusch et al. 2012).  
Faecal-oral, oral and respiratory routes of transmission have been the suggested 
mechanisms of viral spread (Gjoerup et al. 2010) and this is supported by the finding that 
JCPyV and BKPyV can be found in sewage samples and rivers. DNA of HPyVs has been 
detected in tonsillar tissue, indicating a possible point of entry (Gjoerup et al. 2010).  The 
mode of MCPyV transmission is unclear. Intrauterine transmission does not appear to 
occur, as no MCPyV DNA is detectable in miscarried or aborted fetuses (Sadeghi et al. 
2010). However, it is clear that MCPyV infection occurs in early infancy (Kean et al. 2009; 
Chen et al. 2011; Tolstov et al. 2009). MCPyV DNA is common on the human skin 
(Schowalter et al. 2010; Foulongne et al. 2010). In a study of 60 environmental surface 
samples, 45 (75.0%) were positive for MCPyV DNA and in a few of these samples the 
viral DNA was even protected from DNase degradation, suggesting that it was viral DNA 
encapsidated inside infectious virus particles (Foulongne et al. 2011). As well as the skin, 
MCPyV DNA has also been found in the upper aerodigestive tract, in the digestive system 
and in the saliva, but was less frequently found in lung and genitourinary system samples 
(Loyo et al. 2010). MCPyV has also been found in the lower respiratory tract (Babakir-Mina 
et al. 2010) and on the tonsils (Chen et al. 2011). The age distribution of samples from 
immunocompetent or immunocompromised patients indicates that Merkel cell virus 
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DNA is more frequent in adults (8.5%) than in young children (0.6%). The notable age 
difference of MCPyV possibly reflects a major dissimilarity in the lifecycles of this virus 
(Kantola et al. 2009). MCPyV can also persist in inflammatory monocytes and is spread 
along monocyte migration routes (Mertz et al. 2010). MCPyV has also been found in the 
lymphatic system (Toracchio et al. 2010).  
BKPyV is a nephrotropic virus and is associated with urinary tract pathologies in 
transplant patients (Jiang M, et al. 2009). BKPyV- associated nephropathy occurs in 2-5% 
of renal transplant patients. Viral reactivation during these complications is robust 
(Bonvoisin et al. 2008; O'Donnell et al. 2009). JCPyV is neurotrophic and is the etiological 
agent of progressive multifocal leukoencephalophaty (PML) in immunosupressed patients 
(Jiang et al. 2009). PML is a disease caused by JCPyV reactivation in the central nervous 
system and JCPyV can be detected in the cerebral spinal fluid (Drews et al. 2000). 
Recently, JCPyV was associated with male infertility as semen from infertile men 
contained JCPyV DNA in 25% of the cases compared to 11% in controls (Comar et al. 
2012). So far, it has not been possible to associate BKPyV or JCPyV with human cancers 
(Gjoerup et al. 2010). Recently, a high prevalence and  a high viral load of TSPyV DNA has 
been found in TS lesions, implying a causal relationship between TSPyV infection and TS 
disease (Kazem et al. 2012). Importantly, the vast majority of HPyVs have not been 
associated with any human disease. This is true even for KIPyV and WUPyV, which were 
originally detected in respiratory samples of symptomatic children (Norja et al. 2007). 
 
1.6 Merkel Cell Polyomavirus (MCPyV) 
 
Merkel cell polyomavirus (MCPyV) was discovered at the University of Pittsburgh in 2008, 
similar to other polyomaviruses, it is a non-enveloped, icosahedron shaped, small, double 
stranded DNA virus that is phylogenetically classified into the mammalian 
Orthopolyomavirus genera (Johne et al. 2011). Polyomavirus ability to induce neoplastic 
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transformation in cell culture and neoplasias in vivo have been well documented (Cheng et 
al. 2009) however none had been consistently and convincingly linked with human cancer 
until the discovery of MCPyV and the discovery of MCPyV, as an integrated part of MCC, 
represents the first accepted association of a specific human cancer with the presence of 
a polyomavirus genome. About 80% of Merkel-cell carcinomas contain the MCPyV 
genome. The virus is clonally integrated into the cancerous cells and it has a characteristic 
set of mutations only found in cancer cells, but not when it is detected in healthy skin 
cells. Direct proof for this oncogenetic mechanism comes from studies showing that 
inhibition of production of MCPyV proteins causes MCPyV-infected Merkel carcinoma 
cells to die but has no effect on malignant Merkel cells that are not infected with this 
virus. MCC that do not contain MCPyV genomes, - which account for about 20% of 
Merkel-cell carcinomas, appear to have a separate and as-yet unknown cause. 
 
1.6.1 MCPyV discovery  
 
Merkel cell polyomavirus (MCPyV) was discovered using a technique called Digital 
Transcriptome Subtraction (DTS) (Feng et al. 2007). DTS became a practical approach to 
detect new viral agents associated with human diseases. cDNA from MCC tumor tissues 
were exhaustively sequenced to generate a high fidelity transcriptome database of MCC 
tumors. An in silico subtraction of known human sequences from RefSeq, mitochondria, 
assembled chromosomes, and immunoglobulin sequences in NCBI databases removed the 
majority of human sequences resulting in the identification of candidate nonhuman, 
suspect pathogen sequences for further examination. 2395 sequences were identified as 
non-human candidates and these candidates were then analyzed using low-stringency 
alignment to viral databases. This analysis resulted in the discovery of a new member of 
the polyoma virus family. 
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1.6.2 Genomic organization of MCPyV 
 
MCPyV is a typical polyoma virus in many ways. It is a non-enveloped, double-stranded 
DNA viruses and has a ~5.4kb (5.2-5.4kb) genome that is divided into early (ER) and late 
(LR) coding regions by a noncoding regulatory region (NCRR). The early region (ER) 
encodes a large T antigen (LTAg), a small T antigen (sTAg) and a 57kT antigen (analogous 
to the SV40 17-kT antigen (Zerrahn et al. 1993), all of which share a 78 amino acid stretch 
in the N-terminus. These three proteins are expressed from a multiply spliced mRNA 
with frame changes as shown in Figure 1.10. The late region (LR) encodes 3 capsid 
proteins (VP1, VP2 and VP3) that are expressed after the start of viral DNA replication. 
These structural proteins self-assemble into ~55 nm diameter icosahedron viral particles 
(Tolstov et al. 2009; Pastrana et al. 2009). Unlike the other polyomaviruses, MCPyV does 
not encode an agnoprotein (Sariyer et al. 2011; Jay et al. 1981) or VP4 (Fischer et al. 1972). 
Little is known about the kinetics and regulation of MCPyV late gene expression because 
virus replication studies have been limited. 
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The MCPyV NCRR region contains a 71 bp viral origin of replication (ori). This sequence 
includes an AT-rich tract (helps in DNA melting) and 8 GAGGC pentanucleotide 
sequences that bind MCPyV LTAg. The NCRR also contains bidirectional transcriptional 
promoters and regulatory elements for early and late viral gene expression. Additional 
studies have identified an MCPyV encoded miRNA-MCPyV-mir-M1 (Seo et al. 2009). 
Further studies in MCPyV encoded miRNAs and their potential targets in normal and 
MCC tumor tissues are needed to understand their function. 
 
1.6.3 Tumor specific signature mutations 
 
The MCPyV large T antigen contatins the canonical LTAg domains that are present in 
other polyomavirus family members (Pipas 1992; Ahuja et al. 2005). As shown in Fig. 1.11, 
LTAg also encodes origin binding and helicase/ATPase regions needed for viral replication 
(Shuda et al. 2008).  
However, the LTAg found in MCC has a premature stop codon that truncates the LTAg 
protein, eliminating its C-terminal domains (Shuda et al. 2008; Martel-Jantin et al. 2012), 
including the orgin binding and helicase domains. Despite these truncation mutations 
removing the replication functions of MCPyV LTAg, they occur after the LXCXE 
retinoblastoma-binding motif and do not appear to interfere with other N-terminal LTAg 
domains (Shuda et al. 2008). These two independent mutation events: viral integration and 
T antigen truncation appear to play a mechanistic role in the development of MCC. Both 
events are suspected to be relatively rare and this may be why MCC occurs so 
infrequently.  Importantly, as MCC occurs most commonly in sun exposed areas, UV 
exposure may promote one of both of these mutations. 
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1.7 Virus-like particles 
 
Virus-like particles (VLPs) are similar to viral particles except that VLPs lack viral 
genomes. They are non-infectious, but have similar morphologies and cell tropism as the 
natural virus from which they are derived. They still show comparable cellular uptake and 
intracellular trafficking as the natural virus (Petry et al. 2003). VLPs are typically formed by 
expressing the structural genes of the virus and allowing particles to assemble. VLPs have 
been used as a model to understand viral entry and other process related to infection and 
cell tropism. Most importantly, VLPs have been shown to be useful in vaccine 
development or for gene therapy. 
 
1.7.1 History 
 
When Crawford and collaborators in 1962 were purifying MPyV by CsCl density 
gradients, they found two bands with different densities. The band with the lower density 
was shown to consist of empty capsids without any genes (Crawford et al. 1962). Later 
Michel et al (Michel et al. 1967) and Winicour (Winocour 1968) infected mouse kidney 
cells in culture with MPyV, and they found that the cells were not only producing virions 
with MPyV DNA, but also produced particles carrying host DNA, and they called these 
latter particles pseudovirus. They also realized that these particles could be of potential 
therapeutic value (Michel et al. 1967; Winocour 1968). 
Viral capsid proteins can be expressed in bacteria or eukaryotic cells, where they self-
assemble into virus-like particles (VLPs), also known as pseudo capsids. Already in 1978, 
the MPyV major capsid protein VP1, was chromatographically purified and formed 
pentamers that appeared similar to native virus pentamers (Brady et al. 1978). In 1986 
Salunke and collaborators showed that VP1 pentamers subsequently self-assembled into 
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capsid-like structures of the same size and shape as native virus particles (Salunke et al. 
1986). They concluded that the minor capsid proteins VP2 and VP3 were not required 
for capsid formation. Montross later produced VLPs by expressing the VP1 gene in insect 
cells by baculovirus expression (Montross et al. 1991). VLPs that lack viral DNA and RNA 
have been produced from different viruses, such as HPV (Rose et al. 1993), hepatitis B 
(Miyanohara et al. 1986), HIV (Gheysen et al. 1989; Delchambre et al. 1989) and bluetongue 
virus (French et al. 1990). VLPs can be used to vaccinate against the analogous virus. VLPs 
can also be used as carriers for other molecules, for example foreign DNA in gene 
therapy or proteins in immunotherapy. 
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1.8 Proteomics 
 
The human genome project opened new frontiers in medical research, but genome 
sequences are not sufficient to fully describe the biological characteristics and molecular 
processes that take place in the sequenced organisms. In recent years, genomic research 
has given way to a new discipline, proteomics, which has the potential to revolutionize 
the study of molecular and cellular processes. Proteomics represents the systematic study 
of the different properties of proteins, using a variety of approaches with the aim of 
providing a detailed description of the structure, function and control mechanisms of 
biological systems. 
If we consider proteomics, based on the classical definition, the simultaneous study of a 
large number of proteins of a particular cell line or organism, the term can be traced back 
to 1975 (O'Farrel 1975, Klose 1975, Scheele 1975) which was applied to the mapping of the 
proteins obtained from Escherichia coli, the mouse and from the guinea pig by 2-
dimensional electrophoresis. These researchers aimed to construct databases of proteins 
of a given species, so as to be able to compare different patterns of protein expression. 
However, this idea was not completely realized because, even high resolution gel 
electrophoresis does not provide the identity to any of the separated proteins.  
Furthermore, biological samples are often limited in quantity and in gel electrophoresis 
separation techniques many proteins are not visualized or are obscured by the presence 
of neighboring abundant proteins. One of the first methods used for protein identification 
was sequencing by Edman degradation (Edman 1949), which allows for the identification 
of numerous proteins by providing short amino acid sequences from the N-terminus of 
the protein, or later from peptides. Around the 1990’s, the application of mass 
spectrometry (MS) to protein characterization has supplanted many of these techniques, 
because it provides a sensitive and rapid analysis of proteins.  Initially, the analysis of 
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proteins by mass spectrometry still relied on the separation of proteins by gel 
electrophoresis, followed by digestion with sequence specific proteases, such as trypsin. 
The principle reason why peptides are analyzed rather than proteins is because peptides 
represent an information rich set of fragments of the same protein that more easily gives 
sufficient information to uniquely identify a protein. The introduction of this powerful 
analytical method was also accompanied by the availability of the entire sequence of the 
principle experimental model systems, as well as the human genetic code in public 
databases. 
The development of proteomics is a direct consequence of the progress achieved in the 
large-scale sequencing of genomic DNA. Without this information, it is particularly 
difficult to identify proteins using mass spectrometry.  
It is in this historical context that in 1994, at the first meeting on two-dimensional 
electrophoresis in Siena, the term proteome was coined. The proteome is defined as the 
protein complement to the genome and consequently its study is referred to as 
"proteomics" (Wilkins et al, 1996). 
 
1.8.1 From the genome to the proteome 
 
With the accumulation of large numbers of DNA sequence databases, the researchers 
found that much information on the biological functions of cells could not be obtained 
solely from the study of genes. The transcriptome analysis (the entire set of mRNAs 
transcribed from the genome of a cell) provides an indication of which genes are active in 
a particular cell, but does not give indications about the proteins that are expressed or 
their functions. In fact the knowledge of the sequence of a gene within the DNA molecule 
does not give us information on whether, or when, that particular gene will be 
transcribed and translated, and what the final gene product will be or what will be its 
localization or its role within the cell. In addition, in response to external or internal 
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stimuli, proteins can be modified, which can have a profound impact on their function, 
The proteome is also dynamic and varies in response to external factors and differs 
substantially between the different cell types of the same organism. Finally, it is important 
to think about how proteins, not genes, determine the phenotype of a cell, because it is 
the proteins that are responsible for performing and regulating cellular functions.  
Therefore, proteomic studies are important for connecting the link between the genomic 
information and the biochemical properties of the cell. The characterization of the 
proteomes of different cells is important to understanding how alterations in genomic 
activity can cause different phenotypes and pathological conditions. 
 
1.8.2 The applications of proteomics 
 
Initially, proteomics focused on the development of a series of methods to study the 
proteome and obtain a more complete picture of the protein content of the cell. With 
the eventual goal of being able to study all the protein products expressed in a cell, 
including all isoforms, all post-translational modifications, mapping protein interactions, 
etc. (Figure 1.13). 
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Through the use of mass spectrometry techniques, proteomics can be used to address 
three relevant types of biological problems: 
a. The identification of proteins; 
b. Quantification and expression analysis of protein profiles; 
c. The study of post-translational modifications (PTMs) of gene products (Aebersold, 
Mann 2003). 
Traditionally, three types of application to proteomics are considered: expression 
proteomics, which consists of qualitative and quantitative analysis of protein expression; 
structural proteomics, which aims to map the structure of protein complexes or proteins; 
and finally functional proteomics, whose goal is to study the protein profile in a given 
biological sample to better understand the functional organization at the molecular level 
(Figure 1.14). 
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1.8.3 Expression proteomics 
 
Studies on RNA expression levels in mammalian systems have demonstrated that there is 
only a poor correlation between the protein expression of a given cell and mRNA levels. 
This lack of a strong correlation can be explained by the different stabilities of a particular 
mRNA and the protein it produces (Vogel, Marcotte 2012). In addition, the transcriptome 
varies from one cell to another in response to numerous physiological signals including: 
stress, changes in the surrounding environment, disease, stage in cell cycle, etc.  
RNA transcription is just the beginning of a cascade of events that leads to the synthesis 
of a protein. The mRNA can undergo alternative splicing, editing and polyadenylation 
processes, which result in the creation different mRNA and protein isoforms. Finally, 
proteins are subjected to more than 300 naturally occurring post-translational 
modifications including proteolysis, phosphorylation, glycosylation, acetylation (Patterson, 
Aebersold 2003). 
 
1.8.4 Structural proteomics 
 
The goal of structural proteomics is to predict the three-dimensional structure of all 
proteins. Determining the structure of proteins and how they organize themselves to 
form complexes is important for understanding the behavior of a particular protein. The 
definition of the structure of a protein is required to understand the functional 
relationships between proteins, ligands or other cofactors, and is important for rational 
drug design. 
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1.8.5 Functional proteomics 
 
The objective of functional proteomics is to define the biological function of proteins 
whose role is still unknown, and to identify protein-protein interactions in vivo, in order 
to describe the biological network. 
 
1.8.6 The study of post-translational modifications 
 
Post-translational modifications (PTMs) can be any modification to a protein. These 
modifications alter the primary structure of a protein and can have profound effects on its 
functionality. We know that typically more than one protein is generated from a single 
gene. Indeed, one of the most striking discoveries of this new post-genomic era is that the 
old paradigm of “one gene-one protein” is usually not valid. 
Some PTMs, such as phosphorylation or methylation, are reversible, while others remain 
as a permanent mark until the protein is degraded. Of all the post-translational 
modifications known today (Krishna, Wold 1993), only a few have been studied 
systematically (Mann, Jensen 2003). So far, the most studied modification is 
phosphorylation, which is estimated to modify ~80% of all proteins. It is possible to 
analyze virtually all PTMs through mass spectrometry. This approach is based on the fact 
that the modifications give rise to specific fragments with altered masses, which forms a 
characteristic pattern that can be used to identify the modification itself. 
 
1.8.7 Proteomics techniques 
 
A typical proteomics experiment begins with sample preparation. The goal of sample 
preparation is to produce a sample that can be analyzed by mass spectrometry that still 
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represents the original sample. Typically this involves cell lysis or other extraction 
procedures and efficient lysis typically requires the presence of detergents or other 
agents that are incompatible wiyh the downstream analysis. Downstream steps, such as 
filtration or electrophoresis, are typically used to remove these agents. The proteins are 
subjected to digestion with sequence specific proteases to create a complex mixture of 
peptides. Importantly, each unique protein, including those generated by alternative 
splicing or post-translational modifications, produce a unique set of peptides. Mass 
spectrometry is used to analyze these peptides, which can then be mapped back to 
proteins in the sample. 
A mass spectrometer can be split into two parts, the ionization source and the mass 
analyzer.  Importantly, a mass spectrometer can only measure charged molecules, which 
is why an ionization source is required. For biological samples, Electrospray Ionization is 
the most commonly used source. The major advantage of ESI, or electrospray ionization, 
is in its ability to produce charged gaseous ions directly from a liquid solvent system by 
creating a fine spray of highly charged droplets in the presence of a strong electric field 
(Figure 1.15). 
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The sample solution is typically sprayed from the tip at high voltage and evaporation 
causes the droplet size to rapidly decrease, while the surface charge density rapidly 
increases. Ions are transferred to the gas phase as a result of their Coulombic expulsion 
from the droplet and are then directed into a mass spectrometer through a series of ion 
lenses. Importantly, ESI allows the convenient coupling of the mass analyzer to 
chromatography systems, such as HPLC, which allows for the easy analysis of complex 
mixtures of peptides. 
The most widely used analyzers are quadrupole mass filters, quadrupole ion traps, Fourier 
transform ion cyclotron resonance spectrometers, and time-of-flight mass analyzers. The 
time-of-flight instruments are the simplest: the ions are periodically accelerated by an 
electric field and then passed into a field free drift tube. The time it takes for an ion to 
pass through the drift tube is directly related to its mass and charge. The other mass 
analyzers typically use an oscilating electric field for determining the mass to charge ratio. 
For example, in an ion trap, an oscillating electric field is used to “trap” ions in a stable 
orbit inside the mass analyzer. The amplitude or frequency of the electric field is altered 
to successively eject, and detect, molecules based on their mass to charge ratio. In any 
case, a mass spectrum is created in which the mass to charge ratio is plotted vs the 
intensity of the detected signal. 
In tandem mass spectrometry a single ion is selected and then fragmented inside the mass 
spectrometer. Typically the sample is collided with an inert gas between two mass 
analyzers, which results in their fragmentation by collision-induced dissociation (CID) 
(Hoffmann et al. 2007 Mass Spectrometry: Principles and Applications). Often used 
combinations of analyzers are the triple quadrupole or quadrupole-TOF combinations.  
Following this round of fragmentation, a second mass spectrum is collected, which is 
referred to as the MS/MS spectrum. It is possible to select an ion in an MS/MS spectra and 
subject it to another round of CID, which would produce an MS/MS/MS spectrum, and 
this process can repeated upto about 10 times which would result in an MS10 spectrum. 
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In a typical proteomics experiment, the masses of a group of tryptic peptides is measured 
and then one peptide is subjected to CID and the masses of the fragments are analyzed by 
the second mass analyzer (Figure 1.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Performing MS/MS increases the amount of information in a peptide digest and results in 
many more protein identifications and allows for the efficient identification of PTMs. For 
example, a protein can be unambiguously identified by just one or two peptide MS/MS 
spectra. When the analysis is coupled to chromatography, especially HPLC, the MS/MS 
workflow can handle mixtures of 1000s of unique proteins and can map post-translational 
modifications at the amino acid level (Yates et al. 1996). Currently, it is possible to identify 
>4000 proteins from a single microgram of whole cell lysate in less than 60 minutes. 
The MS/MS spectra generated by peptides are typically analyzed by a process called 
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spectral matching, in which the MS/MS spectra are compared to theoretical spectra 
generated from sequence databases. This comparison is made more efficient by using 
sequence specific proteases, which limits the number of theoretical spectra that need to 
be created, and by only comparing experimental and theoretical spectra that have a 
matching mass. Importantly, PTMs must be accounted for at this stage, as they will affect 
the mass of the peptides as well as the masses of the fragments in the MS/MS spectra. 
Typically, only a few PTMs can be searched at a time, but a growing number of algorithms 
are being developed that can perform the global analysis of PTMs (Bern  et al. 2012). 
 
1.9 Aim of the project 
 
The principal objective of my project is the proteomic analysis of the MCPyV viral particle 
and the capsid proteins. Importantly, host proteins associated with the capsid were 
discovered and a number of post-translational modifications of the capsid proteins were 
also identified. Assays for transformation and for viral production will be important for 
determining the relevance of these interactions. 
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2. MATERIAL AND METHOD 
 
2.1 Materials 
 
2.1.1 Suppliers 
 
General laboratory chemicals were of analytical grade and obtained from Sigma-Aldrich 
Company Ltd. or Merck Chemicals Ltd. General disposable plasticware was supplied by 
Sterilin Ltd., Sarstedt Ltd, VWR International Ltd. and Eppendorf Ltd. All tissue culture 
plasticware was obtained from FalconTM Gilson Inc and Sarstedt Ltd. 
 
2.1.2 Bacterial Strains 
 
Strain: SIG10 ULTRA Electrocompetent Cells 
Genotype: F-mcrAΔ(mrr-hsdRMS-mcrBC)endA1recA1Φ80dlacZΔM15ΔlacX74araD139 
Δ(ara,leu)7697galU galK rpsL nupG λ-tonA (StrR) 
Source: Sigma-Aldrich 
 
2.1.3 Preparation of competent prokaryotic cells 
 
The SIG10 E. coli were plated on LB Agar (Luria-Bertani) without antibiotic and grown at 
37°C overnight.  A single colony was 5 mL of LB (Luria-Bertani) liquid medium and grown 
at 37°C while shaking overnight. The overnight growth of E. coli was diluted 1:100 into 
prewarmed LB (Luria-Bertani) broth and grown at 37°C in a shaker until the optical 
density (OD600) was between 0.4 and 0.5. The growth flask is placed on ice for 30 
minutes and the bacteria harvested by centrifugation. The supernatant is removed and the 
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cells resupended in 250 mLs of sterile ice cold water. The cells are centrifuged and the 
water removed. The cells are resuspended in 3 mL of ice cold 10% glycerol in water and 
single use aliquots frozen at -80°C. 
 
2.1.4 Transformation of Bacteria 
 
Thaw 50 µL of Electrocompetent Cells in an ice bath and add 1–2 µL of the transforming 
DNA solution directly into the thawed cell suspension. Mix gently to ensure even 
distribution and subsequent incubation on ice for 30 minutes. Transfer the mixture of 
cells and DNA to a cold 0.1 cm electroporation cuvette (Sigma-Aldrich), applies an 
exponential decay wave pulse using an ECM 399 electroporation system (BTX). 
Immediately add 1 mL of LB (Luria-Bertani) medium (precooled in an ice bath), then 
transfer the mixture to another tube. Incubate by shaking (160–250 rpm) for 1hr at 37°C. 
Plate an appropriate amount of culture on selective medium and Incubate overnight at 
37°C. Single colonies were isolated. Each colony was used to inoculate 5 mL of LB 
containing antibiotics and incubated in the orbital shaker overnight. 
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2.1.5 Antibodies 
 
Table 2.1A: Primary Antibodies used for western blots 
Primary 
Ubiquitin (P4D1) 
mouse Cell 
Signaling #3936 
anti-AAV 
VP1/VP2/VP3 
mouse B1 #61058 
Progen 
Monoclonal Anti-β-
Actin−Peroxidase 
mouse #A3854 
Sigma 
Anti-acetyl Lysine 
antibody-ChIP 
Grade #ab21623 
abcam 
 
Dilution/Assay 
 
1/1,000 Western 
blot 
 
1/500 Western blot 
 
1/30,000 Western 
blot 
 
1/1,000 Western 
blot 
 
Table 2.1B: Secondary Antibodies used for western blots 
 
 
Secondary 
 
Anti-mouse IgG, 
HRP-linked Cell 
Signaling #7076 
 
Anti-mouse IgG, 
HRP-linked Cell 
Signaling #7076 
 
 
-------- 
 
Anti-rabbit IgG, 
HRP-linked Cell 
Signaling #7074 
 
Dilution/Assay 
 
1:1,000–1:3,000 
Western blot 
 
1:1,000–1:3,000 
Western blot 
 
-------- 
 
1:1,000–1:3,000 
Western blot 
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2.1.6 Plasmid DNA 
 
 pwM2m (VP1 and VP2 dual expression) (Pastrana et al. 2010).  
 ph2m (high VP2 expression) (Tolstov et al 2009).  
 pEGFP-N3 is an expression vector that allows the expression of EGFP (Green 
Fluorescein Protein) (Addgene) 
 
2.1.7 Cell Lines 
 
2.1.7.1 HEK 293TT  
 
HEK 293TT (Human Embryonic Kidney cells) cells, a gift from Dr. Lawrence Banks Tumor 
Virology lab ICGEB (Buck et al. 2004). HEK 293TT cells were grown in DMEM media 
(Sigma-Aldrich) supplemented with 10% fetal bovine serum (Gibco), 50 U/mL penicillin 
(Sigma-Aldrich), 100 ng/mL streptomycin (Sigma-Aldrich).  
 
2.2 Molecular biology techniques 
 
2.2.1 DNA digestion 
 
Restriction enzyme digests were performed on plasmid DNA for clonal analysis or 
isolation of DNA fragments. Restriction enzymes were purchased from NEB and DNA 
digestion was performed in the buffer suggested by the Double Digest Finder tool in NEB 
website (www.neb.com). Reactions were conducted in a reaction volume of 50 µL and 1 µg 
of DNA was cut in preparative digestions. 
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2.2.2 Plasmid DNA Purification (Mini and Maxi-Prep) 
 
Plasmid DNA from bacteria cells was purified using the GenElute Plasmid Miniprep Kit 
(Sigma-Aldrich) using the manufacturer instructions. Breifly, cells from a 5Ml LB overnight 
culture were pelleted by centrifugation at 7,000 rpm for 5 minutes and lysed using the 
provided buffers. The DNA was bound to the GenElute columns and the purified DNA 
was eluted in 50 µL ddH20 and stored at -20°C. The high scale plasmid DNA purification 
(Maxi-prep) started from 100 mL o f  overnight culture. The cells were pelleted by 
centrifugation and plasmid DNA was extracted and purified using the GenElute™HP 
Plasmid Maxiprep Kit (Sigma-Aldrich) according to the manufacturer’s instructions.  The 
purified DNA (a typical yield is 100 µg) is eluted in 200 µL of ddH20 and stored at -
20°C. The concentration of purified DNA was determined using a nanodrop 
spectrophotometer. 
 
2.2.3 SDS-PAGE Gel Electrophoresis and Western Blot  
 
Protein samples were supplemented with 6X Laemmli sample buffer (Sigma-Aldrich) and 
boiled for 10 minutes. The samples were separated by 10% bis-Tris SDS-PAGE 
(https://openwetware.org/wiki/Sauer:bis-Tris_SDS-PAGE,_the_very), with 0.5% 
Chloroform or Trichloromethane CH3Cl (Sigma-Aldrich) for stain-free detection. The gels 
were run for 1 hr at 110/125 mA/gel (start) to 70/80 mA/gel (end) and then electro-
blotted onto PVDF membranes (Millipore). The transfer was performed at 200 mA for 
2hrs. The membranes were blocked at room temperature for 2hrs in PBS buffer 
supplemented with 0.1% Tween-20 (Sigma-Aldrich) and 5% skim milk (w/v) (Sigma-Aldrich) 
or Bløk-CH Noise Cancelling Reagents for Chemiluminescence Detection (Millipore). The 
blocked membranes were then incubated with the appropriate primary antibodies (Table 
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2.1A), diluted in the blocking buffer and incubated with the membranes overnight at 4°C. 
The membranes were washed extensively with PBS supplemented with 0.1% Tween-20 
(Sigma-Aldrich), and then incubated for 1h with a horseradish peroxidase (HRP)-
conjugated secondary antibodies (Table 2.1B). After extensive washing, the blots were 
developed with enhanced chemi-luminescence reagents (ECL+) (Biorad) following the 
manufacturer’s instructions. The membranes were visualized on a ChemiDoc™ Imaging 
Systems (Biorad). 
 
2.2.4 Colloidal Blue Coomassie G-250 Staining  
 
To visualize proteins after SDS-PAGE, the gels were washed once with ddH2O and 
incubated for one hour at room temperature with Colloidal Blue G-250 Coomassie 
solution (10% (w/v) (NH4)2SO4 (Sigma-Aldrich), 20% C2H5OH (Sigma-Aldrich), 0.4% (w/v) 
Coomassie Brilliant Blue G-250 (Biorad) and 3% H3PO4 (Sigma-Aldrich)). The gels were 
washed with ddH2O in order to remove the background staining and to enhance the 
visualization of protein bands (Modified protocol from Kang et al. 2002).  
 
2.3 Pseudovirions (PsV)  
 
2.3.1 Production 
 
For MCPyV pseudovirus (PsV) production, 10 x 10 cm tissue culture dishes with 3-4x106 
HEK 293TT cells in 10 mL growth medium were prepared and incubated at 37°C, 5% 
CO2 for 24 hrs to allow attachment of the cells to the dish. The cells were co-transfected 
using the corresponding plasmid DNAs, encoding the MCPyV late proteins VP1 and VP2 
at a 1:3 ratio and the Gaussia luciferase or pEGFP-N3 plasmid reporter using calcium 
phosphate transfection. For the calcium phosphate transfections, HEK 293TT cells were 
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grown to 50%-70% confluence and a reaction mixture, made up of 445 µL sterile H2O, 50 
µL of 2.5 M CaCl2 (Sigma-Aldrich), 8 µL of specific plasmid DNA and 2 µL of pEGFP-N3 
plasmid, were added to 500 µL of 2X BBS reagent while bubbling. The mixture was 
immediately added to the growth media of the cells and incubated at 37°C.  Efficiency of 
transfection was visualized 48 hrs after transfection using an inverted fluorescent 
microscope using the GFP filter set and then the cells were harvested. The cells were 
harvested by resuspension in growth medium and centrifugation at 1,900 rpm for 5 
minutes. The pellet was washed with 1 mL DPBS, and the cell suspension was transferred 
to a siliconized 2 mL screw-top tube and centrifuged at 1,900 rpm for 5 minutes at 4°C. 
The pellet was resuspended in lysis buffer, at 100 million of cells per mL of lysis buffer, 
and incubated at 37°C for 24 hrs to allow capsid formation. The cell suspension was 
incubated on ice for 5 minutes before adding 0.17 volumes 5 M NaCl. Cell debris were 
removed by centrifugation at 10,000 rpm for 5 minutes at 4°C and the clarified 
supernatant was transferred to a fresh 1.5 mL siliconized tube. The pellet was 
resuspended in 300 µL DPBS/0.8 M NaCl and centrifuged for a second time at 10,000 
rpm for 10 minutes at 4°C. The supernatants were combined and 1 µL benzonase (100 
units) was added and incubated at 37°C for 1h. The crude extract was harvested by 
centrifugation (10,000 rpm / 10 minutes / 4°C) and collected in a new 1.5mL siliconized 
tube. A small aliquot of the crude extract was taken and analyzed by SDS-PAGE. The 
remaining crude extract was used for VLP purification. 
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2.3.2 Purification of pseudovirions  
 
Pseudovirions were purified on an Iodixanol (OptiPrep TM) density gradient. 27%, 33% and 
39% Iodixanol solution in DPBS / 0.8 M NaCl was prepared from the 60% (w/v) Iodixanol 
stock solution and layered into Ultra-clear centrifuge tubes (1/2x2 in.) (Beckman). The 
tubes were covered with Parafilm and incubated for 3 hrs at room temperature to allow 
softening of the inter-phases. Approximately 0.5 mL of the crude extract was gently 
overlayed onto the top of the gradient and centrifuged in SW-55Ti rotor (Beckman) at 
55,000 rpm (234,000 g) for 210 minutes at 16°C. After centrifugation, the VLP band was 
visible as a light grey layer a little over a third of the way up the gradient. The VLPs were 
harvested by puncturing the bottom of the tube slightly off center with a syringe needle. 
An initial 1 mL fraction was collected followed by 250 µL fractions. The collected 
fractions were put on ice immediately. The MCPyV VLPs are usually found in fractions 3-
5. Fraction screening is performed by silver staining or Coomassie staining of SDS-PAGE 
gels. The fractions were stored at -80°C.  
 
2.3.3 Pseudovirus Infection  
 
To test of the purified PsV fractions for PsV infection activity, purified fractions were 
tested in constant 1: 1,000 dilutions. HEK 293TT cells were infected at 70-80% confluency 
with pseudo virus. After 24 hrs the infection media was replaced with fresh warmed 
maintenance media. Viral titer was visualized directly using an inverted fluorescent 
microscope and the GFP filters. 
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2.4. Mass spectrometry sample preparation 
 
2.4.1 In-solution Digestion  
 
Dithiothreitol (DTT) (Sigma-Aldrich) was added to a final concentration of 5 mM and the 
sample was heated to 55°C for 10 minutes. Iodoacetamide or Chloroacetamide (Sigma-
Aldrich) was added to 15 mM and the reaction was allowed to proceed for 1 hr at room 
temperature. Trypsin (Promega) was then added at a ratio of ~1:20 followed by digestion 
for overnight at 42°C. The digested sample is desalted and concentrated using STAGE 
tips (Rappsilber et al. 2007).  
 
2.4.2 In-gel Digestion  
 
Samples separated by SDS-PAGE were stained with Commassie Blue as previously 
described. Visualized bands, or discrete areas of the gel, were excised using a scalpel and 
chopped into ~1 mm3 pieces. Reduction and alkylation steps are performed similarly to 
the in-solution digest protocol and then subjected to extensive washing with 20 mM 
Triethyl Ammonium Bicarbonate (Sigma-Aldrich), pH 8.5 in 50% Acetonitrile (ACN) 
(Sigma-Aldrich). The gel pieces were dehydrated with 100% Acetonitrile (Sigma-Aldrich) 
and then 20 ng/µL trypsin (Promega) was added to completely cover the gel pieces and 
the digestion was allowed to proceed overnight at 42°C. The supernatant was harvested 
and any remaining peptides were extracted from the gel by sonicating for 20 minutes with 
0.1% Formic acid (FA) (Sigma-Aldrich). Recovered tryptic peptides are then purified using 
filter tips as described.  
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2.4.3 Acetylation protocol 
 
The MCPyV pseudoviruses Optiprep gradient fractions were incubated for 1hr at 25°C 
with 50mM Acetic Anhydride (Sigma-Aldrich) (final 5mM) The reaction was stopped with 
100mM NH4HCO3 (Sigma-Aldrich) (final 10mM). Once the incubation was performed, the 
loading buffer was added to the sample and boiled for 5 minutes, then centrifuged and 
loaded into SDS-PAGE. 
 
2.4.4 Stage Tips  
 
Stage tips were prepared with reverse phase filters (EmporeTM 3M). The volume of the 
filter disk and the tips are determined based on the amount of sample used. A small core 
of the reverse phase filter is punched out of the filter using a 2.5 mL combi-tip (Sarstedt 
Ltd) and then lodged near the end of a 20 or 200 µL pipette tip (Gilson Inc). Loading, 
washing and elution steps are performed by pushing the appropriate solvent over the tip.  
 
2.4.5 LC/MS-MS Analysis  
 
Chromatographic separation was accomplished using 3 µm C12 resin (Phenomenex) 
packed into a 75 µm x 15 cm fused silica capillaries (Polymicro) using an EASY-nLC II 
system (Bruker Daltonics) at a flow rate of 500 nL/min. 90 minutes gradients from 100% 
buffer A (99.9% water with 0.1% FA) to 60% buffer B (100% Acetonitrile) were used to 
develop the column. The column effluent was sprayed directly into an AmaZon ETD 
Iontrap mass spectrometer (Bruker Daltonics) using a custom electrospray interface.  
Data collection was controlled by the HyStar program (Bruker Daltonics) using a data-
dependent acquisition mode. MS spectra were acquired in the range of m/z 380 –1600 
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followed by maximum of five MS/MS analyses. The typical duty cycle was approximately 2 
seconds. The precursor selection was based on peak intensity and all charge states were 
selected except for 1+, which was excluded. Dynamic exclusion was set to allow each 
peak to be analyzed 3 times in a 1 minute window. 
 
2.5 Data Analysis  
 
2.5.1 X!Tandem  
 
Data analysis was performed on 3 independent replicates for each experimental 
condition. Data from each experiment was merged and the searches were performed on 
both merged data and on individual experimental runs using the X!Tandem search engine 
(Fenyö et al., 2003). Data was searched against the UniProt human database (forward and 
decoy). Trypsin was selected as the protease with a maximum of one missed cleavage 
allowed. Carbamidomethyl was set as a complete modification and partial oxidation of 
methionine and partial deamidation of glutamine and asparagines were also allowed in the 
search parameters. MS tolerance was set to 0.5 Da while MS/MS tolerance was set to 0.3 
Da. 
  
76 
 
 
3. RESULTS 
 
The main objective of my project is the proteomic analysis of the MCPyV viral particle 
and of the capsid proteins. I produced MCPyV VLPs in tissue culture cells, purified the 
VLPs and analyzed the VLPs by mass spectrometry. I was able to identify a number of 
PTMs on the viral capsid proteins as well as >90 host proteins that co-purified with the 
VLPs. VLPs were produced using two plasmids provided by Christopher B. Buck (Figures 
3.1 A and B), which are needed to produce Virions in mammalian cells. 
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Transfection of HEK293-TT with the two plasmids results in the expression of VP1 and 
VP2 and the production of VLPs. Initially, I attempted to produce viral capsids using just 
the pwM2m (Eash el al 2004) plasmid, since it encodes both VP1 and VP2. However, 
there was very low VP2 expression. Therefore, I included the plasmid ph2m in the 
transfection to improve the ratios of VP1 and VP2 (Schowalter et al, 2013). HEK293-TT 
cells were transfected using a modified calcium phosphate transfection protocol (Figure 
3.2) with the ratio of plasmids favoring VP1 expression (3:1). In addition a plasmid 
expressing GFP (Figure 3.1 B) was used to estimate transfection efficiency and for other 
studies, as the GFP plasmid is efficiently packaged into the VLPs. The expression of the 
capsid proteins was allowed to proceed for 48 hours and the virus like particles were 
purified. The virions were liberated from the cells by hypotonic lysis and the virions 
matured for 16-24 hours. Following maturation, the virions were purified using an 
Optiprep gradient and 12 fractions were collected. 20 µL of the resulting fractions were 
analyzed by SDS-PAGE stained with Coomassie (Figure 3.3) and Silver (Figure 3.4). 
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The qualitative characteristics of the protein extracts were evaluated by observing the 
electrophoretic separation by SDS-PAGE, which allowed the visualization of the proteins. 
The gels, shown in figures 3.3 and 3.4, represent the proteins fractionated by Optiprep 
gradient. 
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The fractions containing virions were identified by the presence of VP1 and were typically 
found in the higher density fractions. The fractions containg mature virions, as well as the 
bands corresponding to VP1 and VP2 were analyzed by mass spectrometry (Figure 3.7), 
which verified the presence of MCPyV capsids. Importantly, the mass spectrometry of 
purified virus revealed the presence of a number of cellular proteins, including the core 
set of 4 histones and a number of other proteins involved in DNA metabolism or 
transcription. 
Western blotting was used to analyze the separation on the Optiprep gradients produced 
from cells that were making VLPs GFP. These samples were blotted using an αGFP 
antibody (αGFP-HRP 1:500) to test the relative amount of contaminating cellular proteins 
in the VLP fractions. GFP immunoreactivity was found at the beginning and end of the 
Optiprep gradient but was not found in any of the fractions containing VLPs. These 
results indicate that the Optiprep gradient efficiently purified the VLPs from the majority 
of cellular proteins (Figures 3.5 and 3.6). 
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In order to test the presence of higher order complexes, I used ultrafiltration to 
fractionate the sample based on size and the resulting fractions were analyzed by SDS-
PAGE (Figure 3.8). 
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Virtually all the proteins in these fractions remained in the concentrate, indicating that 
they are part of higher order complexes greater than 100 kDa and further indicate that 
the VLP preparation is not contaminated by free cellular proteins. 
MS analysis was performed on the VLP containing fractions, either by in solution digest or 
on individual bands that were cut from the gel. The bands were proteolytic digested with 
trypsin and the resulting peptides were extracted from the gel. Protein identification was 
performed by nano LC-MS/MS and the resulting spectra were searched using the 
X!Tandem search engine. 
Analysis of these samples by mass spectrometry identified 93 proteins. Gene ontology 
analysis reveals that many of these proteins are involved in the life cycle of other viruses, 
transcription, DNA replication and repair, protein folding, homeostasis and other types of 
nucleic acid binding proteins (Table 3.1). Table 3.2 contains the results from the LC-
MS/MS analysis containing the most reproducible proteins. 
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Table 3.1 Detailed information of the protein pathways identified with GO analysis from the GPM. The 
results were filtered based on p-value rate and only those results with a p-value < 0.05 are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
pathway ID pathway description     p-value 
GO:0016032 viral process      3.42e-16 
GO:0071822 protein complex subunit organization     2.41e-15 
GO:0019058 viral life cycle       3.08e-14 
GO:0019083 viral transcription      9.59e-14 
GO:0019080 viral gene expression     2.73e-13 
GO:0043933 macromolecular complex subunit organization   4.38e-13 
GO:0006605 protein targeting      6.19e-13 
GO:0051084 de novo posttranslational protein folding   5.7e-12 
GO:0006457 protein folding      7.39e-12 
GO:0034655 nucleobase-containing compound catabolic process  5.12e-10 
GO:0015031 protein transport      3.82e-06 
GO:0010467 gene expression      6.09e-06 
GO:0090304 nucleic acid metabolic process    6.1e-06 
GO:0006461 protein complex assembly     6.28e-05 
GO:0070271 protein complex biogenesis     6.28e-05 
GO:0042981 regulation of apoptotic process    0.000105 
GO:0006259 DNA metabolic process     0.000841 
GO:0006310 DNA recombination     0.00245 
GO:0006974 cellular response to DNA damage stimulus   0.00347 
GO:0071158 positive regulation of cell cycle arrest    0.0045 
GO:0032508 DNA duplex unwinding     0.00797 
GO:0044774 mitotic DNA integrity checkpoint    0.00974 
GO:0006977 DNA damage response, signal transduction by p53  
                   class mediator resulting in cell cycle arrest   0.0177 
GO:0072331 signal transduction by p53 class mediator   0.0202 
GO:0075733 intracellular transport of virus    0.0226 
GO:0031571 mitotic G1 DNA damage checkpoint    0.0248 
GO:0042769 DNA damage response, detection of DNA damage  0.0303 
GO:0006281 DNA repair      0.0307 
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STRING was used to map the known interactions between these 93 proteins and 91 of 
these proteins are known to form interactions with each other (Figure 3.9). 
In addition, the mass spectrometry data was searched for the PTMs of VP1. The search 
focused on phosphorylation, ubiquitinylation and acetylation as these are the most 
common PTMs (Figure 3.10). This resulted in the identification of 14 of phosphorylation 
sites, 6 acetylation site, and 7 of ubiquitinylation sites.  Analysis by scan site indicated that 
a number of kinases are likely to phosphorylate VP1, and although a prevalence of proline 
directed sites were found by mass spectrometry, none of these were identified as 
potential sites of known proline directed kinases, such as the cdks. Importantly, there is 
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an antagonistic relationship between acetylation and ubiquitinylation as these two 
modifications target lysine residues.  In fact, we find some lysine residues that carried the 
ubiquitin mark or the acetyl mark, while 5 of the residues could carry either mark (Figure 
3.10). The function of these modifications is currently unclear. 
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Table 3.2 Identification of proteins co-purified through Optiprep gradient and analyzed by mass 
spectrometry ESI-IonTrap with the most relevant proteins are highlighted in red. 
% 
measured 
% 
corrected 
unique total Description 
79 100+ 41 689 VP1 [Merkel cell polyomavirus] 
37 54 25 133 HSP90AB1:p , heat shock protein 90 alpha family class B member 1 
[Source:HGNC Symbol;Acc: HGNC:5258 ] 
56 64 23 248 ACTG1:p , actin gamma 1 [Source:HGNC Symbol;Acc: HGNC:144 
] 
17 25 13 43 HSP90AA1:p , heat shock protein 90kDa alpha (cytosolic), class A 
member 1 [ Source: HGNC 5253 ] 
48 58 17 56 ATP5B:p , ATP synthase F1 subunit beta [Source:HGNC 
Symbol;Acc: HGNC:830 ] 
29 40 19 51 EEF2:p , eukaryotic translation elongation factor 2 [Source:HGNC 
Symbol;Acc: HGNC:3214 ] 
40 60 15 121 TUBB:p , tubulin beta class I [Source:HGNC Symbol;Acc: 
HGNC:20778 ] 
37 53 14 54 EIF4A1:p , 
12 18 15 39 DHX9:p , DExH-box helicase 9 [Source:HGNC Symbol;Acc: 
HGNC:2750 ] 
31 58 15 92 EEF1A1:p , eukaryotic translation elongation factor 1 alpha 1 
[Source:HGNC Symbol;Acc: HGNC:3189 ] 
15 20 11 42 UBA1:p , ubiquitin like modifier activating enzyme 1 [Source:HGNC 
Symbol;Acc: HGNC:12469 ] 
14 21 11 19 HSP90B1:p , 
29 37 10 49 ENO1:p , enolase 1 [Source:HGNC Symbol;Acc: HGNC:3350 ] 
23 31 12 23 HNRNPM:p , heterogeneous nuclear ribonucleoprotein M 
[Source:HGNC Symbol;Acc: HGNC:5046 ] 
19 25 10 28 EEF1G:p , 
13 18 8 20 HSPA1A:p , heat shock protein family A (Hsp70) member 1A 
[Source:HGNC Symbol;Acc: HGNC:5232 ] 
7.1 10 2 2 HIST1H2BG:p , histone cluster 1 H2B family member j 
[Source:HGNC Symbol;Acc: HGNC:4761 ] 
7.7 11 6 21 PARP1:p , poly(ADP-ribose) polymerase 1 [Source:HGNC 
Symbol;Acc: HGNC:270 ] 
16 19 4 6 PCNA:p , proliferating cell nuclear antigen [Source:HGNC 
Symbol;Acc: HGNC:8729 ] 
6.5 9 4 5 HSPH1:p , heat shock protein family H (Hsp110) member 1 
[Source:HGNC Symbol;Acc: HGNC:16969 ] 
8.7 30 3 22 VP2 [Merkel cell polyomavirus] 
3.9 6 2 3 HSPA8:p , heat shock protein family A (Hsp70) member 8 
[Source:HGNC Symbol;Acc: HGNC:5241 ] 
7.3 10 3 3 HSPD1:p , heat shock protein family D (Hsp60) member 1 
[Source:HGNC Symbol;Acc: HGNC:5261 ] 
4.8 8 2 2 H2AFY2:p , H2A histone family member Y2 [Source:HGNC 
Symbol;Acc: HGNC:14453 ] 
2.7 4 2 2 DDX3X:p , DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked [ 
Source: HGNC 2745 ] 
2.2 3 2 2 COL6A2:p , collagen type VI alpha 2 chain [Source:HGNC 
Symbol;Acc: HGNC:2212 ] 
 
 
In order to begin testing if any of the identified proteins are packaged inside the capsid, I 
treated the purified VLPs with acetic anhydride. This results in the non-specific acetylation 
of surface exposed lysine residues, which can then be detected using an anti-acetyl-lysine 
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antibodies (Figure 3.11). VP1 is acetylated upon acetic anhydride treatment and no 
acetylated proteins were detected in the absence of acetic anhydride treatment. 
Importantly, the histones are not acetylated regardless of the treatment indicating that 
the capsid is able to exclude acetic anhydride under the conditions used and that the 
histones packaged into the capsid do not carry an acetyl mark and are probably not 
transcriptionally active. Analyzing these acetic anhydride treated samples by mass 
spectrometry is one of my future aims, as this should allow me to determine which 
proteins are inside and outside the capsids, as those inside the capsids will not become 
acetylated in response to acetic anhydride. 
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4. CONCLUSIONS 
 
Viruses are under tremendous evolutionary pressure and there are a number of ways that 
organisms use to combat viral infection. However, once the virus enters the cell, which is 
not so obvious as there are more defense mechanisms of the cell to prevent it, it begins 
to exploit the cellular structures and processes to decompress their genetic load and 
start production replication and these processes depend on a variety of interactions 
between viral and host proteins. 
While, the interactions of viral proteins with cellular proteins are clearly important, our 
understanding of these interactions, especially outside the replicative life cycle, is typically 
incomplete. Many viruses dramatically remodel the host’s cellular pathways to their own 
aims, and it is often not clear why certain pathways are targeted, especially in cases like 
HIV, where there can be a long period of dormancy, or in cases such as polyomavirus, 
where there is usually very little pathology until the host’s immune system is 
compromised. In addition, there are several unanswered questions on the mechanism of 
virus assembly and packaging, including uncovering the cellular proteins that participate in 
these process and whether or not the cellular proteins that are packaged inside the 
virions play a role in the next infective cycle.  
I produced VLPs of MCPyV by transfecting HEK293TT cells with plasmids that 
overexpress two viral proteins: VP1 and VP2. This results in the self assembly of capsids 
that behave similarly to the infective virions. The VLPs were purified with Optiprep 
gradients, which separate proteins by their apparent densities. The VLPs were analyzed by 
ultrafiltration, SDS-PAGE, and western blotting, which revealed that the VLPs were highly 
purified and that most proteins were part of higher order complexes. Mass spectrometry 
(MS) was exploited to identify the viral and cellular proteins in the VLP preparation. Only 
two MCPyV proteins were identified, VP1 and VP2, and a number of PTMs were 
identified on VP1. The role that these modifications play in the MCPyV lifecycle is not 
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clear, but they may increase the functions of VP1 as I also usually found the corresponding 
unmodified residue. 
The VLPs also contained as many as 93 cellular proteins. This data set is enriched GO 
terms relating to the viral lifecycle and a database of protein : protein interactions 
revealed that 91 of these proteins can be found as part of the same network. Of these 91 
proteins, I have chosen three possible cellular proteins that could interact with the 
protein VP1, namely PARP1, Histone and HSP90, for further discussion. 
PARP-1 is a nuclear protein, whose main role is to identify DNA single-strand breaks 
(SSB) and signal to the enzymatic apparatus involved in SSB repair. PARP-1 modifies itself 
as well as the chromatin proteins involved in the repair process. PARP-1 attaches a string 
of ADP-ribose molecules to the target protein. Viral chromatin is enclosed in an 
icosahedral capsid of 72 pentamers of the main capsid protein VP1, with each pentamer 
associated with one VP2 protein (Eckhart 1990). Furthermore, VP1 interacts with the 
entire viral genome in mature particles, (Carbone et al. 2004) suggesting that VP1 can 
contribute to modulating or maintaining the compaction of chromatin of the encapsulated 
viral DNA. The condensation of the minichromosome is initially promoted by the histone 
linker H1 until it is removed by VP1 during the final maturation of the viral particles (Yuen, 
Consigli 1985). A possible role played by PARP-1 could be the remodeling of chromatin 
through the modification of histone and transcription factors and in the modulation of 
viral gene expression (Carbone et al. 2006).  
Early viral transcription has been shown to be reduced by competitive PARP inhibitors in 
3T3 cells and almost abolished in PARP-1 knockout fibroblasts and wild-type fibroblasts 
when PARP-1 was silenced by RNA interference. (Carbone et al. 2006). Carbone and 
collaborators have seen that from in vitro experiments the viral protein VP1 stimulates 
the enzymatic activity of PARP-1 and binds non-covalently. (Carbone et al. 2006). Then it 
could be that PARP-1 packs inside the virion, so that it is already present when it is 
needed to promote viral transcription. 
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Histones are basic proteins that make up the structural component of chromatin. The 
large number of basic residues in Histones promotes the interaction between Histones 
and the negatively charged DNA, which forms structures called nucleosomes. Histones 
are among the most conserved eukaryotic proteins during the course of evolution, in fact 
most changes to their sequence are lethal, which confirms their fundamental role in 
chromatin compaction. However, unlike cellular chromatin, polyomavirus 
minichromosomes do not have histone H1 (Fang et al. 2010). Histone H2A is one of the 
five major histone proteins involved in chromatin structure in eukaryotic cells and was 
identified by mass analysis. To date, five families of histones are known; which are called 
H1 / H5, H2A, H2B, H3 and H4 (Cox et al. 2005). The histone H2A is composed of non-
allelic variants (Bosch et al. 1995). The term “histone H2A” is intentionally non-specific 
and refers to a variety of closely related proteins that often vary only by some amino 
acids. The variant that resulted from the mass analysis is MacroH2A a variant similar to 
H2A and is encoded by the H2AFY gene. This variant differs from H2A due to the 
addition of a fold domain in its C-terminal queue. The MacroH2A variant is expressed in 
the X chromosome inactive in females (Costanzi et al. 1998). This last statement allows us 
to speculate on the fact that there is a correlation between the incidence of MCC on 
male patients compared to female patients, explaining the fact that the histone protein is 
transported by the virion. We know that the modification of histone proteins can lead to 
a change in function, such as phosphorylation that occurs due to rupture of the dsDNA 
(Talbert et al. 2010) or acetylation, however the modification of H2A is currently 
underway of research. 
Histones are also cationic proteins involved in antimicrobial activities. In vertebrates and 
invertebrates, the histone H2A variant is involved in the host immune response acting as 
an antimicrobial peptide (AMP) (Arockiaraj et al. 2013). It could be that the virus, by 
encapsulating this protein for example by preventing its acetylation, prevents it from 
acting as an antimicrobial agent. In fact, in treating the virion sample with acetic anhydride 
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it was found that the histone protein does not acetylated, presumably because it is 
protected by the capsid itself. 
Hsp90 is an abundant cellular chaperone that interacts with many proteins, including 
transcription factors, kinases, ligases, structural proteins, ribosomal components and 
metabolic enzymes (Zuehlke et al. 2015). Hsp90 is also known to be involved in the 
lifecycle of many viruses.  Hsp90 participates in virus replication, the folding of structural 
proteins and assembly of virions (Geller et al. 2012). Given that Hsp90 is known to be a 
protein that binds microtubules (Giustinian et al. 2009; Fostinis et al. 1992; Echeverria & 
Picard 2010), it would be interesting to know if this chaperone mediates the interaction 
between VP1 and microtubules. The role of the HSP90 protein is not clear, it could 
simply be trapped in the virion after being involved in the assembly of the virion, or since 
it is used by estrogens to control the interaction of the estrogen receptor transcription 
factor to be involved in the life cycle of the virus or in the formation of the MCC. 
Estrogens are present in significant amounts in both men and women and in women are 
present in high quantities at the beginning of menstrual periods and puberty and then 
decrease with age. The primary function of estrogens is the development of female 
secondary sex characteristics, while in men estrogen helps in sperm maturation. Estrogen 
helps in protein synthesis and increases platelet adhesiveness and decreases antithrombin 
III, increases HDL and triglycerides while decreasing LDL, helps fetal development. The 
reduction of estrogen causes a significant lowering of mood and may predispose to 
depression. Estrogens improve collagen content and quality, increase skin thickness and 
improve interface blood supply by acting through estrogen receptors. The number of 
receptors varies in different parts of the body. The parts of the body with the greatest 
number of receptors are found on the face, above the thigh and the chest. This allows us 
to hypothesize that the HSP90 protein closely related to estrogen is somehow involved 
with MCC and would justify the fact that HSP90 is transported by the virion. Males also 
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have estrogen receptors but, to a lesser extent than women, estrogen levels in the male's 
blood are greater than those in post-menopausal women. 
There are a number of questions that remain about the proteins that interact with the 
VLPs. The most important question is whether they play a role in the lifespan of the virus. 
It is possible that these proteins do not play a role in the lifecycle.  However, if they do 
play a role, it seems likely that they either function early in the infective cycle, to promote 
a successful infection, or they are involved in the very late stages of capsid formation and 
packaging. The functions of these proteins are best determined in the background of a 
wild type virus, so these experiments should be repeated using a native virus.  The 
function of the associated proteins can be determined by disrupting their expression, 
using siRNA or CRISPR/Cas9, in the packaging cell lines and then assessing various 
properties of the resulting virions. For example, the yield of viral particles and their 
infectivity will give a good indication of whether the knocked down protein is required 
during the late stages or the early stages of the MCPyV life cycle. 
In addition, I currently do not know if the identified proteins are packaged inside the 
virion or if they are associated with the outside of the VLP. I have already begun to 
address this question by treating the purified VLPs with acetic anhydride.  The acetic 
anhydride will covalently modify accessible lysine residues and proteins within the virion 
appear to be resistant to this modification, as the histones were not modified when the 
VLPs were treated with acetic anhydride. Importantly, another round of MS will be 
required to identify which proteins are modified by acetic anhydride treatment, and are 
on the outside of the particle, and which proteins are not, and are on the inside of the 
particle. I initially hoped that labeling with trihalo compounds could also be used for this 
purpose (appendix 1), but this modification is always incomplete and would not be 
suitable for these experiments. 
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5. APPENDIX Development of Trihalo Labeling for Protein Analysis 
 
5.1 Abstract 
 
Protein electrophoresis and western blotting are important techniques for protein 
detection and quantification. However, these techniques are long and labor-intensive 
processes and traditional protocols require approximately 2 days to complete. In addition 
to the many steps, such as sample preparation, gel casting, protein electrophoresis and 
transfer, membrane blocking followed by antibody incubation, etc., there is often a need 
to repeat parts of the process to ensure equal protein loading and to collect data that can 
be quantitated. Therefore, I investigated the performance of a “stain-free” procedure to 
confirm that the stain-free technology provides an easy and rapid protein visualization 
that can be used for the normalization of protein loading and the verification of transfer 
efficiency. The stain-free procedure is based on the UV-induced reactions of Trihalo 
organic compounds with tryptophan residues in proteins. The reaction of Trihalo 
compounds with tryptophan residues results in the creation of a new fluorophore that 
can be detected using a suitable imager. This chapter presents an optimized protocol that 
allows the proteins on a polyacrylamide gel to be viewed both before and after protein 
transfer. Finally, I adapted the TriHalo labeling to in solution reactions so that it may be 
useful for gaining structural information about protein complexes. There are many 
advantages of using TriHalo-based analysis including high sensitivity, wide linear dynamic 
range for quantitative accuracy, reproducibility, cost-efficiency, timesaving, ease of use, 
and compatibility with downstream protein identification such as western blotting and 
mass spectrometry (MS).  
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5.2 Introduction 
 
5.2.1 Stain-free detection, basics of the UV light induced reaction 
 
In stain-free detection a trihalo compound is used to induce the fluorescence of tryptophan 
amino acids when irradiated under UV light. Examples of suitable Trihalo compounds 
include: Trichloromethane (Chloroform TCM), 2, 2, 2-trichloroethanol (TCE), trichloroacetic 
acid (TCA), 2, 2, 2-tribromoethanol (TBE), 2, 2, 2-trifluoroethanol (TFA), These and other 
similar trihalo compound react with indole containing compounds, such as tryptophan in the 
presence of UV light. The characterization of indole derivatives reacting with chloroform, 
and other trihalo and dihalo compounds in photoreactions were reported by Ladner and 
co-workers (Ladner et al. 2004). For example, the two principal products formed in a 
photochemical reaction between chloroform and tryptophan are derivatives at carbon 
positions 4 (4-imido tryptophan) and 6 (6-formyl tryptophan) (Figure 5.1). Importantly, 
the reaction with trihalo compounds results in enhanced fluorescence from the modified 
tryptophan which can be easily detected (Figure 5.2). 
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The presence of chloroform in the reaction adds a formyl group (or Aldehyde group −CHO) 
to the aromatic chromophore (Figures 5.1 and 5.3) (modified from Ladner et al. 2006). In 
contrast, when no trihalo compound is present, N-formyl-kynurenine (NFK) (Figure 5.1B) 
is the only photoreaction product. After an initial photoreaction of indole with a trihalo 
compound, further reactions with water result in the complete release of the halogen 
atoms (Figure 5.4). Although the modifications added by other trihalo compounds are 
different from chloroform, for most of the compounds tested, the fluorescence excitation 
and emission wavelengths are similar to those obtained from reactions with chloroform. 
Trichloroethanol (TCE) reacts more quickly than chloroform, but in an analogous way it 
adds the halo compound carbon skeleton to the indole ring, modifying the indole ring 
carbon atom of the reactant to a carbonyl. Trichloroacetate (TCA) mass addition (+44 
AMU) implies that a carboxyl group (C (=O)OH )is added (Ladner et al. 2007). In particular, 
this product has nearly the same fluorescence properties as the formyl products 
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mentioned above, but has much less intensity. The photoreaction with trihalo compounds 
makes a significant change: it enlarges the conjugated system in the indole chromophore, 
which is not the case with mono halo compounds (Figure 5.3). 
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In stain-free polyacrylamide gels, after protein sample loading, the UV light induces release 
of an electron from the indole ring of tryptophan, this electron reacts with the trihalo 
compound, resulting in the covalent binding of the trihalo compound to the light-activated 
tryptophan residue, due to the high sensitivity of fluorescent detection, this chemistry 
allows for the detection of proteins down to 20–50ng per band. The UV dependent 
addition does not appear to interfere with downstream steps, such as immunoblotting. 
Addition of the trihalo compound enhances the rate of the photochemical reaction that 
produces fluorescence. In fact, chloroform increases the rate of photobleaching of the 
indole fluorophore nine-fold over when no trihalo compound is present, making the rate 
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of the background reaction without trihalo compounds inconsequential (Ladner et al. 
2014). 
A method to fluorescently visualize proteins in polyacrylamide gels using chloroform and 
trichloroacetic acid (TCA) was reported (Kazmin et al. 2002). It consists of soaking the 
gel in TCA, followed by a 300nm UV light illumination in order to obtain a fluorescent 
product. This process depends on tryptophan content. If tryptophan residues are lacking 
in a protein, this protein is not detected; however, in most organisms, at least one 
tryptophan is contained in 90% of proteins and the majority of the proteins lacking in 
tryptophan are less than 10kD in size (Table 5.I). 
 
Table 5.1: Tryptophan (W) content of the predicted proteomes of several model organisms (from UniProt 
database modified from BioRad). 
Species 
Total # 
of 
proteins 
# of proteins 
lacking W 
% of proteins 
lacking W 
# of 
proteins 
> 10kD 
# of proteins 
> 10kD 
lacking W 
% of 
proteins 
>10kD 
lacking 
W 
# of proteins 
< 10kD 
lacking W 
% of 
proteins 
<10kD 
lacking W 
Homo 
sapiens 
40,827 4,209 10.31 37,548 2,754 7.33 1455 3.56 
Escherichia 
coli O:K1 / 
APEC 
4,865 458 9.41 4,754 408 8.58 50 1.03 
Escherichia 
coli (strain 
K12) 
4,181 456 10.91 3,879 325 8.38 131 3.13 
Rattus 
norvegicus 
12,022 1,081 8.99 11,421 745 6.52 327 2.72 
Mus 
musculus 
35,344 3,435 9.72 33,262 2,480 7.46 955 2.70 
Saccharomy
ces 
cerevisiae 
5,815 648 11.14 5,563 491 8.83 157 2.70 
 
 
After stain-free it is possible to proceed with CBB (Coomassie Brilliant Blue) staining and 
visualization (Ladner et al 2004). 
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5.2.2 Stain-free method as a reliable total protein loading control 
 
Western blotting is a biochemical technique that allows the identification of a specific 
protein from complex mixtures of proteins, via the recognition by specific antibodies.  In 
general, the protein mixture is first separated using a polyacrylamide gel, which is 
subsequently transferred onto a membrane support, such as nitrocellulose. 
Western blot analysis is routinely employed for quantifying differences in protein levels 
between samples. To control equal loading and compensate loading differences, 
immunodetection of “housekeeping” proteins (HKPs) is commonly used. HKPs may show 
inconsistency in their expressional level under modifications in experimental conditions, 
for example actin is a frequently used housekeeping gene, but its levels change during the 
cell cycle (Rubin et al. 1978). On the other hand, total protein normalization (TPN) makes 
use of the signal intensity from the entire lane of the sample loaded as a loading control 
for the respective target protein. TPN resolves issues related to stripping and reprobing 
of the membrane, where it is important to ensure that the primary antibody previously 
used is totally removed, leaving no residual signals. Total protein stains, such as Ponceau 
S, Sypro Ruby, Amido Black, have been used for TPN but they can negatively affect 
downstream applications and/or are difficult to image. At the same time, a proper 
verification tool that can also be used for a reliable quantitation would be of a major 
interest for western blot experiments. With trihalo labeling, reprobing steps can be 
avoided, as it does not require HKP immunodetection for normalization, and trihalo 
labeling validates differences in the level of the protein of interest using total protein 
measurement as the loading control (Posch 2013). 
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5.3 Aim of the Appendix 
 
Light dependent reactions with trihalo compounds allows for the rapid fluorescent 
detection of proteins without the need for additional staining or destaining steps.  
Currently, trihalo labeling is only available in commercial precast gels, and I set out to 
optimize trihalo labeling for both qualitative and quantitative analysis of western blots 
with laboratory-made gels. In addition, I adapted the triHalo labeling technique to 
solutions of proteins, rather than being limited to only gel based labeling. This increases 
the versatility of the technique so that it can be used for protein visualization in gels and 
directly on blots and as a tryptophan specific label for the mass spectrometry analysis of 
proteins. These studies show that labeling with trihalo compaunds gels does not 
interference with the analysis of protein samples by mass spectrometry and or western 
blotting. 
 
5.4 Materials and Methods  
 
5.4.1 Materials 
 
Table 5.2: List of chemicals, kits and consumables used. 
 
Product Description; Manufacturer 
Chloroform, TCA, TCE, DCM, TFE, 
TBE, TFA 
Standard chemicals were obtained from Sigma‐Aldrich 
with analytical grade (>99%) 
Bradeford-Protein determination Bio-Rad Laboratories 
Luminol reagent 
Clarity™ Western ECL Blotting Substrate Bio-Rad 
Laboratories 
Mini-PROTEAN TGX Precast Gels Bio-Rad Laboratories 
Protein standard 
PageRuler Plus Prestained (cat. # 1610374) Bio-Rad 
Laboratories and Thermo (cat. #26619) and PageRuler 
Unstained (cat. #1610363) Bio-Rad Laboratories 
PVDF-Membrane Immobilon; Millipore GmbH 
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5.4.1.3 Buffers and solutions 
 
 
Table 5.3: List of buffers and solutions used. 
 
Description Composition 
Laemmli sample buffer (6x) 
7mL 4xTris/SDS pH 6.8 (3.02g Tris; 0.2g SDS; 50mL ddH2O; pH 
6.8); 3.6mL Glycerin; 1g SDS; 0.93g DTT; 1.2mg Bromophenol blue; 
10mL ddH2O 
Bloking solution 5% milk powder in TBS-T or 1% BSA in TBS-T 
PBS Dulbecco´s Phosphate Buffered Saline; Sigma Aldrich 
MOPS Running buffer (10X) 
60.6g Tris base, 104.63g MOPS, 3.8g EDTA powder (MW 372.24), 
10g of SDS powder. 
bis-Tris (3.5X Stock) 
1.25M bis-Tris HCl pH 6.8 (65.40g add ddH2O (200mL) adjust pH 
with HCl 37% and bring the volume to 250mL with ddH2O). 
 
 
5.4.1.4 Software and databases used 
 
Table 5.4: Software used. 
 
Software Manufacturer Use 
Image Lab Bio-Rad Laboratories 
Western blot- and agarose gel analyses Stain-free 
detection activation, visualization and analyses 
The GPM 
The Global Proteome 
Machine Organization 
Proteomics data analysis 
Data analysis 
Bruker 
Bruker Daltonics Mass spectrometry Analysis 
 
  
104 
 
 
Table 5.5: List of antibodies used 
 
Antigen 
 
Origin Animal MW Type Epitope 
β-actin 
Cell Signalling 
#3700 
Mouse 
Monoclonal 45 primary 
Product with synthetic peptide 
corresponding N-Term of human  
β-actin 
p53 
Cell Signalling 
#9282S 
Rabbit 
Polyclonal 53 
primary 
Product with full length human p53 
H3(1B1B2) 
Cell Signalling 
#14269S 
Mouse 
Monoclonal 17 
primary Product with peptide C-Term of 
human H3 
PTEN 
Cell Signalling 
#9188S 
Rabbit 
Monoclonal  54 
primary Product with peptide C-Term of 
human PTEN 
p21 
Santa Cruz  
#sc-397 
Rabbit 
Polyclonal 21 
primary Product with peptide C-Term of 
human p21 
Cofilin 
(D59) 
Cell Signalling 
#3318S 
Rabbit 
Polyclonal 19 
primary Product with synthetic peptide 
surrounding Asp (D) 59 
PCNA 
Santa Cruz  
#sc-25280 
Mouse 
Monoclonal 36 
primary Product with linear peptide 
corresponding to aa 1-261 of human 
PCNA 
ACE_H3 
Millipore 
#06599 
Rabbit 
Polyclonal  17 
primary Product with linear peptide 
corresponding to human H3 
acetylated of N-Term 
p84 
AbCam 
#ab487 
Mouse 
Monoclonal 84 
primary Product with fusion protein 
containing aa 15-574 of human p84 
GFP 
Santa Cruz  
#sc-9996 
Mouse 
Monoclonal 27 
primary Product with synthetic peptide aa 1-
238 of GFP protein 
Actinin 
Santa Cruz  
#sc-17829 
 Mouse 
Polyclonal  100 
primary Product with peptide aa 593-892 of 
human actinin 
mouse IgG 
HRP- 
conjugated 
Santa Cruz  
#sc-17829 goat  
secondary 
 
rabbit IgG 
HRP- 
conjugated 
Santa Cruz  
#sc-17829 goat  
secondary 
 
 
 
5.4.2 Methods 
 
5.4.2.1 Protein quantification by the Bradford method 
 
The assay was performed as described by the manufacturer and a standard curve was 
generated using BSA as a standard. Dilutions of the protein samples were prepared to fit 
the linear range of the calibration curve. 
  
105 
 
 
5.4.2.2 MOPS SDS-PAGE 
 
To prepare stain-free handcast  mini-gels, 10mL of the gel mix stock was mixed with 50µL 
of one of the trihalo compound (Chloroform (TCM), 2, 2, 2-trichloroethanol (TCE), 
trichloroacetic acid (TCA), 2, 2, 2-tribromoethanol (TBE), 2, 2, 2-trifluoroethanol (TFE); 
Dichloromethane (DCM) and 2-Chloro Acetamide (2ClAA) then 100µL APS (10%) and 3µL 
TEMED were added to initiate the polymerization. Prior to loading, the protein samples 
were heat denaturized for 5 min at 95°C.  
 
5.4.2.3 Activation of trihalo-based SDS gel 
 
After electrophoresis, the gel was carefully removed from the cassette and placed on the 
tray of a ChemiDocTM Touch (Bio-Rad Laboratories GmbH) to activate the photochemical 
reaction of the trihalo compound with tryptophan. Activation was done for 45 – 300 
seconds at wavelength 300 nm. 
 
5.4.2.4 Western blot 
 
5.4.2.5 Semi-Dry blot protein transfer 
 
Protein transfer from the gel to a nitrocellulose membrane was carried out using the 
semi-dry blotting procedure (Kyhse-Andersen 1984). Briefly, a transfer membrane and filter 
sheets were cut to fit the measurement of the gel, the filter papers and membrane were 
equilibrated in the transfer buffer for at least 1 minute. A transfer sandwich between two 
electrodes was prepared. The air bubbles were removed from the transfer sandwich and 
the transfer was performed at 60 mA per gel (0.8 mA / cm2) for 90 min. 
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Prior to transfer, UV irradiation of the gel is necessary to modify the tryptophan residues 
in the separated proteins (Ladner et al 2004). UV irradiation was performed on the 
Chemidoc MP System (Bio-Rad Laboratories GmbH), as stated above. Activation of the gel 
is necessary only once as the reaction is covalent and further imaging of the gels or 
membranes is done without another activation step. Afterwards the membranes can be 
imaged on Chemidoc MP System, which verifies the efficiency of protein transfer. 
 
5.4.2.6 Blocking, immunodetection and evaluation 
 
Nonspecific protein binding was blocked by incubating the membrane for 2 h in nonfat 
dried milk powder (5%) in 1x TBS-T or BSA (1%) in 1x TBS-T at RT. After three washing 
steps with 1x TBS-T for 5 min, the membrane was incubated with the corresponding 
primary antibody diluted in blocking buffer on the rotatory mixer (5 rpm, 4°C, O/N). The 
following day, the membrane was washed three times in TBS-T and then incubated with 
the respective secondary antibody in blocking buffer for 1h at RT. In Table 6.6, the 
antibodies used in this work are listed, with the name, type, the producer, host animal, 
dilution and epitope. After a final set of washing steps, the blot was developed with ECL 
reagents (Bio-Rad Laboratories GmbH). The resulting signal was visualized using the 
ChemiDoc MP system and evaluated in the Image Lab program (Bio-Rad Laboratories 
GmbH). 
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5.5 Results 
 
5.5.1 Trihalo labeling technology 
 
Reliable loading controls are required for the proper interpretation of western blots. It is 
important that the blots do not show saturation or inconsistent expression level in 
different samples or experimental conditions. Influenced by these concerns that could 
potentially produce data artifacts, scientific journals are requiring stricter controls and 
imaging methods for quantitative comparisons (https://www.nature.com/nature-
research/editorial-policies/image-integrity). Instead of using an HKP, which results in single 
band loading controls, total protein signals in each lane can be used as a loading control as 
an alternative solution. Trihalo labeling offers a rapid protein visualization method on 
polyacrylamide gels and transfer membranes, and is an ideal alternative to other total 
protein stains such as Ponceau S or Amido Black. In a typical application, trihalo labeling 
only adds an additional 5 minutes of time to the western blotting workflow. 
 
5.5.2 Testing different halo compounds and concentrations 
 
5.5.2.1 Investigation of the optimal halo compound for in-gel visualization 
method.  
 
In this study I explored pre electrophoresis, post electrophoresis and in gel labeling 
protocols and a number of different protocols for trihalo labeling. Initially, I included 
different trihalo compounds into the gel before polymerization.  Compounds were tested 
at 0.5% or 2% and compared to CBB staining. A mix of a constant amount of BSA (1 μg) 
and increasing concentrations of Lysozyme (2.5 - 600 ng) were analyzed to assess the 
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performance of trihalo labeling.  Labeling with TCM and TCE allows for rapid protein 
detection, which is significantly more sensitive than the standard CBB (Figure 5.5). The in-
gel method compared to CBB staining shows that TCE and TCM labeling are more 
sensitive than CBB staining with the minimal detectable limits being 40ng for TCM and 
200ng for CBB. Furthermore, the increasing concentrations of Lysozyme indicated a 
linear relationship between protein amount and labeling strength. While DCM was 
roughly as sensitive as CBB and no proteins were visualized with TFE or TCA (Figure 
5.8). 
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5.5.2.2 Comparison of using different concentration of trihalo compounds for 
in-gel visualization method.  
 
I tested TCM and TCE compounds at different concentrations in the range from 0.025% 
to 2% in-gel visualization method and using the same mixture of BSA and Lysozyme or 
using total lysate of primary MEF cells as the sample. The TCE signal intensity increased 
proportionally with the concentration (Figures 5.5A and 5.5C). I found that TCM was 
problematic, in that it affected the quality of the electrophoresis when added at 1% 
(Figure 5.5B) or greater and that extra care had to be taken to keep the gel from heating 
during the run as this appeared to cause the outgassing of TCM.  
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5.5.2.3 Using trihalo compound for post-electrophoresis staining 
 
I also explored various trihalo compounds reactions with t TCM, TCE, DCM and TBE 
used for post-electrophoresis labeling. After electrophoresis, the gel was incubated in a 
10% solution of one of the trihalo compounds for about ten minutes and Coomassie 
staining was used for comparison. The results show that both TCE and TCM give an 
excellent signal; TBE gave a poor signal, while DCM did not give any signal (Figure 5.6). It 
is unclear why DCM gives a signal when incorporated into the gel, but does not work 
when the gel is incubated in DCM following electrophoresis. The Coomassie blue staining 
of the same gels shows the same intensity all four gels.  
 
5.5.2.4 Trihalo compound reactions in-sample buffer 
 
To determine if the photochemical reaction of the trihalo compound with tryptophan can 
occur in sample buffer, I activated the photochemical reaction in sample buffer 1) before 
and 2) after boiling the sample. In the first case, before boiling the sample, activation of 
the photochemical reaction was achieved with UV light for 5 minutes followed by 
denaturing the samples at 95ºC for 5 min, and loading onto the gel. In the second case, 
where the labeling was performed after boiling the samples, the samples were diluted 
with unmodified sample buffer, followed by boiling at 95ºC for 5 min, the indicated trihalo 
compounds were added to the sample to 1% and  activation of the photochemical 
reaction was also achieved with a 5 minute exposure to UV light. The images were 
captured with the ChemiDoc Touch. I used a sample of BSA treated with TCE 1% as a 
positive control while the different concentrations of lysozyme were treated with 
different trihalo compounds (TCM, TFE, DCM, TCA or TFA). Five trihaol compounds 
were used in this experiment and only TCE and TCM showed a clear and strong signal, 
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while TFE, DCM and TFA give no signal (Figure 5.7). Using TCE in-sample labeling showed 
a higher sensitivity than in-gel labeling as in the first lane of (Figure 5.7) 10 ng of lysozyme 
is clearly visible and indicates that the presence of the bromo-phenol blue does not 
inferfere with the photoreaction.  
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My results indicated that the organic compound can have a strong effect on labeling, as 
there are clear difference in the labeling, where the halogen is the same, but the organic 
carrier is different, for example TCE and TCM. Therefore, I wanted to test the same 
organic carrier, but with different halogens. TCE, TFE, and TBE, were chosen to test the 
effect of different halogens on the labeling (Figure 5.8). TFE resulted in no labeling and the 
photoreaction with TCE and TBE was very similar, except at the lowest concentrations of 
TBE and TCE, where TCE was clearly stronger. 
I also tried in gel labeling experiments with TBE, which proved unsuitable, as the TBE 
promoted the polymerization of the gel prior to the addition of TEMED and APS. This 
suggested that TBE is a reactant during the polymerization of the gel and is most probably 
producing free radicals similar to APS. If this were the case, TEMED may be able to 
increase the trihalo labeling, as its main function during acrylamide polymerization is to 
stabilize free radicals. As seen in Figure 5.11, the addition of TEMED to an in solution 
reaction with TCE results in enhanced labeling. Importantly, APS was not able to 
potentiate labeling with TCE. In addition, TEMED or APS alone were also inefficient at 
inducing the fluorescence of tryptophan in the absence of a trihalo compound.  
I also tested the ability of TEMED to increase the labeling with TFE or TBE, and TEMED 
was able to promote the labeling with TCE and TBE, but was not able to rescue the poor 
labeling with TFE (Figure 5.10). 
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5.5.2.5 Compatibility of TCE-based stain-free with western blot.  
 
Western blotting is one of the most common techniques used in modern biological 
research. This method consists of several steps: sample preparation, casting the gel, 
protein electrophoresis and transfer, membrane blocking, incubation with antibodies, 
imaging and analysis. This may be followed by the stripping and reprobing of the same 
blot.  Each of these steps plays a key role in the final detection of proteins and could be 
considered a limitation of this technique. In fact, errors can be made at every stage of this 
process. So, a more practical and reliable modification of this method would be of a major 
interest, for both qualitative protein verification and quantitative analysis. Many of these 
limitations such as sample loading, transfer efficiency and using the wrong loading control 
can be avoided by using trihalo gel labeling. The main step in western blotting is the 
recognition between the antibody and antigen. Therefore to investigate if the TCE-
labeling has any effect on this step of western blot, several antibodies were used to 
confirm the compatibility of TCE-labeled proteins with western blot. 
I tested cellular samples modified by trihaolo compaunds, and then analyzed them by 
Western blot using various types of antibodies and as can be seen from (Figure 6.12). 
I initially tested the trihalo labeling on a crude MCPyV virion sample by running unpurified 
MCPyV preps onto two 10% gels, one with TCE at 0.5% and the other without any 
trihalo compound. Serial dilutions of the same crude preparation were run into both gels 
and the gels were activated for 5 minutes with UV light. The gels were transferred to 
PVDF membranes and subsequently analyzed using anti-GFP and anti-GAPDH antibodies.  
The following day the membranes were developed, acquiring the images of the various 
exposures with the ChemiDoc Touch. We proceeded with the analysis of the 
quantifications and the normalization of the results obtained through the ImageLab 
software. Importantly there was no impairment of either antibody signal following trihalo 
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labeling.  In fact, trihalo labeling resulted in a slight increase in sensitivity.  I followed this 
up by analyzing a panel of antibodies on different samples (Figure 5.11) and trihalo labeling 
did not result in the loss of signal from any of these antibodies. 
 
5.6 Quantification and normalization  
 
5.6.1 TriHalo labeling as a loading control 
 
I also tested the trihalo labeling on a MCPyV virion sample by running crude, unpurified 
MCPyV preps onto two 10% gels, one with TCE at 0.5% and the other without any 
trihalo compound. Serial dilutions of the same crude preparation were run into both gels 
and the gels were activated for 5 minutes with UV light. The gels were transferred to 
PVDF membranes and subsequently analyzed using anti-GFP and anti-GAPDH antibodies.  
The following day the membranes were developed, acquiring the images of the various 
exposures with the ChemiDoc Touch. We proceeded with the analysis of the 
quantifications and the normalization of the results obtained through the ImageLab 
software (Figure 5.12) and this indicated that there was no loss of signal following the 
photoreaction with TCE. 
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5.7 MS analysis of the modifications formed from the photochemical reaction 
of lysozyme with trihalo compounds. 
 
MS analysis of in-gel digested TCE or TCM labeled Lysozyme was performed to 
characterize the modifications formed by the photochemical reaction. I found that the 
photochemical reaction of lysozyme with TCM produced a mass addition of +28 to 
tryptophan, while the photochemical reaction of TCE produced a mass addition of +58 
(Figure 5.13), these mass shifts are in agreement with Ladner et al. 2014. MS analysis was 
able to detect the trihalo modified tryptophan residues and no other trihalo modified 
residues were detected. In all cases tested, MS analysis revealed that the UV-dependent 
reaction of trihalo compounds with tryptophan is inefficient, as there was always 
unmodified or oxidized tryptophan residues. This is true even following the addition of 
Temed to enhance the reaction.  Importantly, this indicates that the trihalo labeling is 
unlikely to inhibit antibody binding, even if the antibody-of-interest binds to tryptophan 
residues, because there will still be a pool of unreacted tryptophans to interact with the 
antibody. 
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5.8 Discussion 
 
A fast stain-free protein visualization method based on the fluorescence of modified 
tryptophan is reported. Precast stain-free gels are already on the market, but the cost for 
routine laboratory use is prohibitively high, therefore I developed a hand casting 
procedure for in gel labeling.  In addition, I also developed a post electrophoresis reaction 
where the trihalo compounds are added after electrophoresis is completed and I also 
developed an in solution procedure that can be used to label prior to electrophoresis, or 
other techniques, such as mass spectrometry.  In fact, the pre electrophoresis and hand 
casted in gel versions of this technique have not yet been established, and several halo 
compounds differing in chemical properties and concentrations were examined to 
determine the best trihalo reagent. 
Trihalo compounds, such as trichloroacetic acid (TCA) and trifluoroethanol (TFE) were 
not useful labeling reagents, as the Trp residues were poorly visible after UV irradiation 
(Data not show). In fact, Ladner reported that the TCA photoreaction has nearly the 
same fluorescence shift as the formyl products of mentioned trihalo compounds, but with 
much less intensity (Ladner et al. 2014).  In addition, TCA has the added difficulty of 
strongly affecting the solubility of proteins in solution and the quality of the 
electrophoresis.  
During the course of these experiments, I noticed that tribromoethanol (TBE) was able 
to initiate acrylamide polymerization prior to the addition of APS and TEMED.  This 
suggests that the TBE was acting to provide the free radicals necessary to initiate the 
polymerization reaction.  I tested if APS and Temed could replace or augment the ability 
of the trihalo compounds to modify tryptophan residues. Importantly, TEMED significantly 
increased the intensity of the labeling with trihalo compounds.  In this regard, TEMED is 
most likely acting to stabilize the free radicals produced by UV irradiation, in much the 
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same way that it stabilizes the free radicals produced by APS during acrylamide 
polymerization.  
In conclusion trichlormethane (TCM) and trichloroethanol (TCE) appear to be the most 
useful trihalo compounds. The main difference between them appears to be related to the 
water solubility of TCM vs TCE. TCM is a hydrophobic solvent, more commonly called 
chloroform, and has limited water solubility. 2% TCM negatively impacted the quality of 
the gels formed and even at lower concentrations of TCM, increased care had to be 
taken during the run, because TCM is also much more volatile than TCE, and heating of 
TCM containing gels creates bubbles in the gel. Therefore TCE was chosen as the most 
optimal trihalo compound.  
In addition, a number of western blots were performed that indicate that trihalo labeling 
does not interfere with most antibody: antigen pairs. This will likely be true even in the 
cases where the epitope contains tryptophan residues, as the mass spectrometry data 
demonstrated that it is very difficult to drive the photoreaction to completion.   
The inability to drive this reaction to completion suggests that this strategy cannot be 
used to gain structural information about a protein, as it will be difficult to relate 
incomplete labeling with solvent accessibility. 
 
5.9 Conclusion 
 
In this work the photoreaction between trihalo compounds and tryptophan residues was 
studied. Some aspects of the stain-free technology were highlighted and confirmed. 
Results indicated that 2, 2, 2-trichloroethanol (TCE) was the best reagent for in-gel 
visualization, in-sample or post electrophoresis labeling. This is largely because TCE is 
highly soluble in aqueous buffers. The protocols I developed are similar to the 
commercially available product and have the same advantages, such as providing 
convenient check-points at different points in the western blotting procedure. The stain-
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free TCE-optimized protocol showed remarkable linearity in given samples. Given these 
points, stain-free detection method fits perfectly in the world of western blotting, offering 
a sensitive and convenient tool for everyday analysis. The TCE optimized approach should 
be integrated into immunoblotting workflows, as an affordable hand cast alternative to 
commercial precast stain-free gels. 
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